Inactive | PROCEDURE: | REFERENCE: | ROCHE REFERENCE: | ||||
Collaboration powered by Smartsheet | Report Abuse | |||||||
1 |
| Revised: 3/12/2024 | |||||
2 |
| ||||||
3 | |||||||
4 |
| . | |||||
5 |
| . | |||||
6 |
| . | |||||
7 | |||||||
8 |
| . | |||||
9 |
| Prisma Health Baptist Parkridge Hospital Laboratory 400 Palmetto Health Parkway Columbia, SC 29212 | |||||
10 |
| Prisma Health Richland Hospital Rapid Laboratory 5 Richland Medical Park Drive Columbia, SC 29203 | |||||
11 |
| ||||||
12 |
| Prisma Health Greenville Memorial Hospital Laboratory 701 Grove Road Greenville, SC 29605 | |||||
13 |
| Prisma Health Hillcrest Hospital Laboratory 729 SE Main Street Simpsonville, SC 29681 | |||||
14 |
| Prisma Health North Greenville Hospital Laboratory 807 N Main Street Travelers Rest, SC 29690 | |||||
15 |
| Prisma Health Patewood Hospital Laboratory 175 Patewood Drive Greenville, SC 29615 | |||||
16 | |||||||
17 |
| . | |||||
18 |
| Prisma Health Cancer Institute – Faris Road 900 W Faris Rd Greenville, SC 29605 | |||||
19 |
| Prisma Health Cancer Institute – Grove Commons 3 Butternut Dr Suite B Greenville, SC 29605 | |||||
20 |
| Prisma Health Cancer Institute – Seneca 131 Lila Doyle Dr Seneca, SC 29672 | |||||
21 |
| ||||||
22 | |||||||
23 |
| REFERENCE: | |||||
24 |
| 10 - 30 ug/mL | 10 - 30 ug/mL | ||||
25 | |||||||
26 |
| Not Detected | |||||
27 | |||||||
28 |
| SERUM: 0 - < 1 Year 2.8 - 4.7 g/dL 1 - 60 Years 3.5 - 5.0 g/dL > 60 Years 3.4 - 4.8 g/dL BODY FLUID: The separation of ascitic fluids into transudates or exudates has been superseded by the division of ascitic fluids into high-gradient or low-gradient fluids as determined by the serum-ascites albumin gradient calculated as (serum albumin) - (ascitic fluid albumin). The gradient is a reflection of the hydrostatic pressure in the portal circulation. Gradients >/=1.1 g/dL are considered high. Specimens of serum and fluid should be drawn the same day. High Values may be seen in: Cirrhosis, Fulminant hepatic failure, Fatty liver, Alcoholic hepatitis, Portal vein thrombosis, Veno-Occlusive disease; Low Values may be seen in Peritoneal carcinomatosis, Tuberculosis, Pancreatic, Connective tissue disease, Nephrotic syndrome, Biliary (without cirrhosis). Pleural Fluid: Serum Albumin Level - Pleural Fluid Albumin Level </=1.2 g/dL is predictive of an exudate. | SERUM: 0 - 3 Days: 2.8 - 4.4 g/dL 4 Days - 13 Years: 3.8 - 5.4 g/dL 14 - 18 Years: 3.2 - 4.5 g/dL >/= 19 Years: 3.5 - 5.2 g/dL BODY FLUID: The separation of ascitic fluids into transudates or exudates has been superseded by the division of ascitic fluids into high-gradient or low-gradient fluids as determined by the serum-ascites albumin gradient calculated as (serum albumin) - (ascitic fluid albumin). The gradient is a reflection of the hydrostatic pressure in the portal circulation. Gradients >/=1.1 g/dL are considered high. Specimens of serum and fluid should be drawn the same day. High Values may be seen in: Cirrhosis, Fulminant hepatic failure, Fatty liver, Alcoholic hepatitis, Portal vein thrombosis, Veno-Occlusive disease; Low Values may be seen in Peritoneal carcinomatosis, Tuberculosis, Pancreatic, Connective tissue disease, Nephrotic syndrome, Biliary (without cirrhosis). Pleural Fluid: Serum Albumin Level - Pleural Fluid Albumin Level </= 1.2 g/dL is predictive of an exudate. | ||||
29 | |||||||
30 |
| < 10 mg/dL | < 11 mg/dL | ||||
31 | |||||||
32 |
| Female: 0 - 14 Days 90 - 273 IU/L 15 Days - 11 Months 134 - 518 IU/L 1 - 9 Years 156 - 369 IU/L 10 - 12 Years 141 - 460 IU/L 13 - 14 Years 62 - 280 IU/L 15 - 16 Years 54 -128 IU/L 17 - 19 Years 48 - 95 IU/L >/= 20 Years 40 - 150 IU/L Male: 0 - 14 Days 90 - 273 IU/L 15 Days - 11 Months 134 - 518 IU/L 1 - 9 Years 156 - 369 IU/L 10 - 12 Years 141 - 460 IU/L 13 - 14 Years 127 - 517 IU/L 15 - 16 Years 89 - 365 IU/L 17 - 19 Years 59 - 164 IU/L >/= 20 Years 40 - 150 IU/L | Female: 0 - 14 Days: 83 - 248 IU/L 15 Days - 11 Months: 122 - 469 IU/L 1 - 9 Years: 142 - 335 IU/L 10 - 12 Years: 129 - 417 IU/L 13 - 14 Years: 57 - 254 IU/L 15 - 16 Years: 50 - 117 IU/L 17 - 18 Years: 45 - 87 IU/L >/= 19 Years: 35 - 104 IU/L Male: 0 - 14 Days: 83 - 248 IU/L 15 Days - 11 Months: 122 - 469 IU/L 1 - 9 Years: 142 - 335 IU/L 10 - 12 Years: 129 - 417 IU/L 13 - 14 Years: 116 - 468 IU/L 15 - 16 Years: 82 - 331 IU/L 17 - 18 Years: 55 - 149 IU/L >/= 19 Years 40 - 129 IU/L | ||||
33 | |||||||
34 |
| If total Alkaline Phosphatase is elevated and labile fraction exceeds 70%- consistent with bone origin. | If total Alkaline Phosphatase is elevated and labile fraction exceeds 70%- consistent with bone origin. | ||||
35 | |||||||
36 | 06/20/22 |
| < 0.35 kU/L Interpretive Data: Less than 0.10 kU/L - Normal: No significant level detected 0.10 - 0.34 kU/L - For Specialists use only: Clinical relevance undetermined 0.35 - 0.70 kU/L - Low: Indicative of ongoing sensitization 0.71 - 3.50 kU/L - Moderate: Indicative of stronger ongoing sensitization 3.51 - 17.50 kU/L - High: Indicative of high level sensitization 17.51 kU/L or Greater - Very High: Indicative of very high level sensitization | ||||
37 | |||||||
38 | 06/20/22 |
| < 0.10 kU/L Interpretive Data: Any detectable level (>/= 0.1 kU/L) of Specific IgE for Peanut Components may be significant. Ara h 1, 2, 3, and 6 are the peanut proteins most linked to systemic allergic reactions, including anaphylaxis. If any one of these four components is positive, the patient has a high risk of systemic allergic reaction when exposed to peanuts, regardless of the whole peanut allergen result. Reactivity to Ara h 9 and non-reactivity to Ara h 1,2,3 and 6 indicates a variable risk of systemic allergic reaction including anaphylaxis. Reactivity to Ara h 8 and Profilin and non-reactivity to Ara h 1,2,3 and 6 indicates a lower risk of a systemic allergic reaction. Reactivity to CCD and non-reactive to Ara h 1,2,3 and 6 indicates lowest risk of a systemic allergic reaction. | ||||
39 | |||||||
40 | 07/07/22 |
| 90 - 200 mg/dL | ||||
41 | 07/07/22 | ||||||
42 |
| < 8.79 ng/mL | |||||
43 | |||||||
44 |
| Female: 0 - 11 Months 5 - 33 IU/L 1 - 12 Years 9 - 25 IU/L 13 - 19 Years 8 - 22 IU/L >/= 20 Years < 55 IU/L Male: 0 - 11 Months 5 - 33 IU/L 1 - 12 Years 9 - 25 IU/L 13 - 19 Years 9 - 24 IU/L >/= 20 Years < 55IU/L | Female: 0 - 11 Months: </=25 IU/L 1 - 12 Years: </=19 IU/L 13 - 19 Years: </=17 IU/L >/= 20 Years: 10 - 35 IU/L Male: 0 - 11 Months: </=25 IU/L 1 - 12 Years: </=19 IU/L 13 - 19 Years: </=18 IU/L >/= 20 Years: 10 - 50 IU/L | ||||
45 | |||||||
46 |
| TROUGH: 0 - 2 Months < 5.1 ug/mL >/= 3 Months 4.0 - 8.0 ug/mL PEAK: 25.0 - 35.0 ug/mL RANDOM: 8.0 - 25.0 ug/mL | TROUGH: 0 - 2 Months < 5.1 ug/mL >/= 3 Months 4.0 - 8.0 ug/mL PEAK: 25.0 - 35.0 ug/mL RANDOM: 8.0 - 25.0 ug/mL | ||||
47 | |||||||
48 |
| 18 - 72 umol/L | Female: 11 - 51 umol/L Male: 16 - 60 umol/L | ||||
49 | |||||||
50 |
| Negative | |||||
51 | |||||||
52 |
| SERUM: 0 - 27 Days 5 - 65 IU/L 28 Days - 70 Years 25 - 125 IU/L >/= 71 Years 20 - 160 IU/L BODY FLUID: Interpretive Data: Peritoneal: Elevated at very high concentrations in pancreatitis. At least several-fold times higher in fluid of pancreatic origin compared to simultaneous values in serum, even in cases of acute pancreatitis. Elevated in pancreatic injury. Pleural Fluid: May be high due to contamination with salivary secretions and food in suspected esophageal rupture. | SERUM: 0 - 14 Days: 3 - 11 IU/L 15 - 84 Days: </=26 IU/L 85 Days - 11 Months: 3 - 58 IU/L 1 - 18 Years: 29 - 118 IU/L >/=19 years: 28 - 100 IU/L BODY FLUID: Interpretive Data: Peritoneal: Elevated at very high concentrations in pancreatitis. At least several-fold times higher in fluid of pancreatic origin compared to simultaneous values in serum, even in cases of acute pancreatitis. Elevated in pancreatic injury. Pleural Fluid: May be high due to contamination with salivary secretions and food in suspected esophageal rupture. | ||||
53 | |||||||
54 |
| 6 - 16 mmol/L | 6 - 16 mmol/L | ||||
55 | |||||||
56 | 07/07/22 |
| 0 - 3 Years: < 100 U/mL 4 - 17 Years: < 251 U/mL >/= 18 Years: < 200 U/mL | ||||
57 | 07/07/22 | ||||||
58 |
| 80 - 120 % | |||||
59 | |||||||
60 |
| No fetal hemoglobin | |||||
61 | |||||||
62 |
| 0 - 14 Days: 23-186 IU/L 15 Days - 11 Months: 23-83 IU/L >/=1 Year: 5-34 IU/L | Female: 0 - 14 Days: </= 155 IU/L 15 Days - 11 Months: </= 63 IU/L 1 - 6 Years: </= 41 IU/L 7 - 11 Years: </= 33 IU/L 12 - 18 Years: </= 23 IU/L >/= 19 Years: 10 - 35 IU/L Male: 0 - 14 Days: </=155 IU/L 15 Days - 11 Months: </= 63 IU/L 1 - 6 Years: </= 41 IU/L 7 - 11 Years: </= 33 IU/L 12 - 18 Years: </=32 IU/L >/= 19 Years: 10 - 50 IU/L | ||||
63 | |||||||
64 | 06/20/22 |
| < 7.0 U/mL Interpretive Data: < 7.0 Normal 7.0-10.0 Equivocal - Recommend to retest the patient after 4-6 weeks. > 10.0 Positive The expected value in the normal population is negative. However, up to 3% of apparently healthy, asymptomatic individuals may have increased levels of B2-Glycoprotein I antibodies. Anti-B2 Glycoprotein I antibodies may be present in the so called antiphospholipid syndrome, often appearing in conjunction with SLE, and sometimes occurring without symptoms of SLE. Clinical manifestations can be thrombosis, recurrent pregnancy loss, thrombocytopenia, hemolytic anemia, and other features such as livedo reticularis, migraines, epilepsy, and others. A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated. Expected values may vary on the population tested. | ||||
65 | |||||||
66 | 06/20/22 |
| < 7.0 U/mL Interpretive Data: < 7.0 Normal 7.0-10.0 Equivocal - Recommend to retest the patient after 4-6 weeks. > 10.0 Positive The expected value in the normal population is negative. However, up to 3% of apparently healthy, asymptomatic individuals may have increased levels of B2-Glycoprotein I antibodies. Anti-B2 Glycoprotein I antibodies may be present in the so called antiphospholipid syndrome, often appearing in conjunction with SLE, and sometimes occurring without symptoms of SLE. Clinical manifestations can be thrombosis, recurrent pregnancy loss, thrombocytopenia, hemolytic anemia, and other features such as livedo reticularis, migraines, epilepsy, and others. A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated. Expected values may vary on the population tested. Rheumatoid factor (RF) can interfere with the determination of IgM anti B2 Glycoprotein I antibodies. | ||||
67 | |||||||
68 |
| Pregnancy: Negative: </= 5 mIU/mL Inconclusive: > 5 - < 25 mIU/mL Positive: >/= 25 mIU/mL Rare false positives have been reported. Positive results should be confirmed with a urine specimen prior to aggressive therapy. Weeks Post Last Menstrual Period: Approx Total B-hCG Range (mIU/mL) 1-10 Weeks: <1.20 - 231,000 11-15 Weeks: 16,996 - 234,990 16-22 Weeks: 6,860 - 50,064 23-40 Weeks: 1,583 - 49,413 The ARCHITECT Total B-hCG assay is cleared for use in the early detection of pregnancy only. It is not approved for any other uses such as tumor marker screening, tumor marker monitoring, etc. and it should not be performed for any other uses. | Pregnancy: Negative: </= 5 mIU/mL Inconclusive: > 5 - < 25 mIU/mL Positive: >/= 25 mIU/mL Rare false positives have been reported. Positive results should be confirmed with a urine specimen prior to aggressive therapy. Weeks Post Last Menstrual Period: Approx Total B-hCG Range (mIU/mL) 1 - 10 Weeks: <1.20 - 231,000 11 - 15 Weeks: 16,996 - 234,990 16 - 22 Weeks: 6,860 - 50,064 23 - 40 Weeks: 1,583 - 49,413 The ARCHITECT Total B-hCG assay is cleared for use in the early detection of pregnancy only. It is not approved for any other uses such as tumor marker screening, tumor marker monitoring, etc. and it should not be performed for any other uses. | ||||
69 | |||||||
70 |
| 0.0 - 0.5 mmol/L 0.6-1.5 mmol/L w/Glucose >/=300 mg/dL Potential for development of problem requiring medical intervention >1.5 mmol/L w/Glucose >/=300 mg/dL May indicate the risk of developing diabetic ketoacidosis (DKA) | 0.0 - 0.5 mmol/L 0.6 - 1.5 mmol/L w/Glucose >/=300 mg/dL Potential for development of problem requiring medical intervention > 1.5 mmol/L w/Glucose >/=300 mg/dL May indicate the risk of developing diabetic ketoacidosis (DKA) | ||||
71 | |||||||
72 |
| 0.0 - 12.0 umol/L | 0.0 - 12.0 umol/L | ||||
73 | |||||||
74 |
| 0 - 14 Days 0.3 - 0.7 mg/dL >/= 15 Days 0.0 - 0.5 mg/dL | 0 - 14 Days: 0.3 - 0.5 mg/dL 15 Days - 11 Months: </= 0.2 mg/dL 1 - 8 Years: </= 0.1 mg/dL 9 - 12 Years: </=0.2 mg/dL 13 - 18 Years: Male: 0.1 - 0.3 mg/dL Female: </= 0.3 mg/dL >/= 19 Years: </= 0.3 mg/dL | ||||
75 | |||||||
76 |
| 0 - 14 Days 0.1 - 9.9 mg/dL >/= 15 Days 0.0 - 1.2 mg/dL | 0 - 14 Days: 0.1 - 9.9 mg/dL >/= 15 Days: 0.0 - 1.2 mg/dL | ||||
77 | |||||||
78 |
| 0 - 23 Hours < 6.0 mg/dL 1 - 14 Days 0.1 - 10.3 mg/dL >/= 15 Days 0.1 - 1.2 mg/dL | 0 - 23 Hours: < 6.0 mg/dL 1 - 14 Days: 0.1 - 10.3 mg/dL >/= 15 Days: 0.1 - 1.2 mg/dL | ||||
79 | |||||||
80 |
| Not Detected | |||||
81 | |||||||
82 |
| Negative | |||||
83 | |||||||
84 |
| Negative | |||||
85 | |||||||
86 |
| 0 Days - 11 Months < 24 pg/mL 1 Year - 5 Years < 30 pg/mL 6 Years - 10 Years < 15 pg/mL 11 Years - 14 Years < 21 pg/mL 15 Years - 20 Years < 20 pg/mL >/=21 Years < 100 pg/mL | This assay is not performed on Roche analyzers. | ||||
87 | |||||||
88 |
| 0 - 74 Years </= 125 pg/mL >/= 75 Years </= 450 pg/mL | 0 - 74 Years: </= 125 pg/mL >/= 75 Years: </= 450 pg/mL | ||||
89 | |||||||
90 |
| SERUM: 0 - 11 Months 8.5 - 11.0 mg/dL 1 - 17 Years 9.0 - 10.5 mg/dL >/= 18 Years 8.5 - 10.4 mg/dL URINE: Random: Male: 0.9 - 37.9 mg/dL Female: 0.5 - 35.7 mg/dL Timed: CA Free Diet 5 - 40 mg/24hr Low to Average Intake 50 - 150 mg/24hr Average Intake 100 - 300 mg/24hr 0 - 11 Years: 2.0 - 4.0 mg/kg/24hr > 12 Years: 1.4 - 4.3 mg/kg/24hr | SERUM: 0 - 11 Months: 8.6 - 11.0 mg/dL 1 - 17 Years: 9.3 - 10.6 mg/dL 18 - 60 Years: 8.6 - 10.0 mg/dL 60 - 90 Years: 8.8 - 10.2 mg/dL >/= 91 Years: 8.2 - 9.6 mg/dL URINE: Random: Male: 0.9 - 37.9 mg/dL Female: 0.5 - 35.7 mg/dL Timed: CA Free Diet 5 - 40 mg/24hr Low to Average Intake 50 - 150 mg/24hr Average Intake 100 - 300 mg/24hr 0 - 11 Years: 2.0 - 4.0 mg/kg/24hr >/= 12 Years: 1.4 - 4.3 mg/kg/24hr | ||||
91 | |||||||
92 |
| Male: < 0.25 mgca/mgcr Female: < 0.33 mgca/mgcr | Male: < 0.24 mgca/mgcr Female: < 0.33 mgca/mgcr | ||||
93 | |||||||
94 |
| WHOLE BLOOD: (Upstate) 0 - 29 Days: 1.00 - 1.50 mmol/L 1 - 6 Months: 0.95 - 1.50 mmol/L >/= 7 Months: 1.16 - 1.32 mmol/L PLASMA: (Midlands) All Ages: 1.09 - 1.30 mmol/L | |||||
95 | |||||||
96 |
| WHOLE BLOOD: (Upstate) 1.16 - 1.32 mmol/L PLASMA: (Midlands) 1.09 - 1.30 mmol/L | |||||
97 | |||||||
98 |
| < 35.1 U/mL | |||||
99 | |||||||
100 |
| < 23.6 U/mL | |||||
101 | |||||||
102 |
| < 35.1 U/mL | |||||
103 | |||||||
104 |
| 4.0 - 12.0 ug/mL | 4.0 - 12.0 ug/mL | ||||
105 | |||||||
106 |
| Not Detected | |||||
107 | |||||||
108 |
| < 3.1 ng/mL | |||||
109 | |||||||
110 | 06/20/22 |
| < 14.0 APL U/mL Interpretive Data: < 14.0 Negative 14.0-20.0 Equivocal - Recommend to retest the patient after 4-6 weeks. > 20.0 Positive Antibody prevalence in autoimmune patients varies widely depending on disease area. The proportion of sera from a normal population found positive for the Cardiolipin IgA covered by the EliA Cardiolipin IgA test is below 5%, increasing with age, and men tend to show higher values. Expected values may vary depending on the population tested. A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated. | ||||
111 | |||||||
112 | 06/20/22 |
| < 10.0 GPL U/mL Interpretive Data: < 10.0 Negative 10.0-40.0 Weak Positive - Recommend to retest the patient after 8-12 weeks. > 40.0 Positive The expected value in the normal population is negative. However, low percentages (up to 5%) of apparently healthy, asymptomatic individuals have been reported to be positive for ACA. Cardiolipin antibodies show the following prevalences in APS: Primary APS: ACA IgG 81%, ACA IgM 40%, ACA IgA 24% Secondary APS: ACA IgG 85%, ACA IgM 65%, ACA IgA 10%. A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated. | ||||
113 | |||||||
114 | 06/20/22 |
| < 10.0 MPL U/mL Interpretive Data: < 10.0 Negative 10.0-40.0 Weak Positive - Recommend to retest the patient after 8-12 weeks. > 40.0 Positive The expected value in the normal population is negative. However, low percentages (up to 5%) of apparently healthy, asymptomatic individuals have been reported to be positive for ACA. Cardiolipin antibodies show the following prevalences in APS: Primary APS: ACA IgG 81%, ACA IgM 40%, ACA IgA 24% Secondary APS: ACA IgG 85%, ACA IgM 65%, ACA IgA 10% A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated. | ||||
115 | |||||||
116 |
| Midlands: | |||||
117 |
| 0 - 2 Months: 53.0 - 84.0 % 3 - 5 Months: 51.0 - 77.0 % 6 - 11 Months: 49.0 - 76.0 % 12 - 23 Months: 53.0 - 75.0 % 2 - 5 Years: 56.0 - 75.0 % 6 - 11 Years: 60.0 - 76.0 % 12 - 17 Years: 56.0 - 84.0 % >/= 18 Years: 58.0 - 84.0 % | |||||
118 |
| 0 - 2 Months 2500 - 5500 Cells/uL 3 - 5 Months 2500 - 5600 Cells/uL 6 - 11 Months 1900 - 5900 Cells/uL 12 - 23 Months 2100 - 6200 Cells/uL 2 - 5 Years 1400 - 3700 Cells/uL 6 - 11 Years 1200 - 2600 Cells/uL 12 - 17 Years 1000 - 2200 Cells/uL >/= 18 Years 856 - 2237 Cells/uL | |||||
119 |
| 0 - 2 Months 35.0 - 64.0 % 3 - 5 Months 35.0 - 56.0 % 6 - 11 Months 31.0 - 56.0 % 12 - 23 Months 32.0 - 51.0 % 2 - 5 Years 28.0 - 47.0 % 6 - 11 Years 31.0 - 47.0 % 12 - 17 Years 31.0 - 52.0 % >/= 18 Years 33.6 - 64.8 % | |||||
120 |
| 0 - 2 Months 1600 - 4000 Cells/uL 3 - 5 Months 1800 - 4000 Cells/uL 6 - 11 Months 1400 - 4300 Cells/uL 12 - 23 Months 1300 - 3400 Cells/uL 2 - 5 Years 700 - 2200 Cells/uL 6 - 11 Years 650 - 1500 Cells/uL 12 - 17 Years 530 - 1300 Cells/uL >/= 18 Years 518 - 1472 Cells/uL | |||||
121 |
| 0 - 2 Months 12.0 - 28.0 % 3 - 5 Months 12.0 - 23.0 % 6 - 11 Months 12.0 - 24.0 % 12 - 23 Months 14.0 - 30.0 % 2 - 5 Years 16.0 - 30.0 % 6 - 17 Years 18.0 - 35.0 % >/= 18 Years 13.0 - 37.6 % | |||||
122 |
| 0 - 2 Months 560 - 1700 Cells/uL 3 - 5 Months 590 - 1600 Cells/uL 6 - 11 Months 500 - 1700 Cells/uL 12 - 23 Months 620 - 2000 Cells/uL 2 - 5 Years 490 - 1300 Cells/uL 6 - 11 Years 370 - 1100 Cells/uL 12 - 17 Years 330 - 920 Cells/uL >/= 18 Years 205 - 924 Cells/uL | |||||
123 |
| 0 - 2 Months 4.0 - 18.0 % 3 - 5 Months 3.0 - 14.0 % 6 - 11 Months 3.0 - 15.0 % 2 - 11 Years 4.0 - 17.0 % 12 - 17 Years 3.0 - 22.0 % >/= 18 Years 4.3 - 26.6 % | |||||
124 |
| 0 - 2 Months 170 - 1100 Cells/uL 3 - 5 Months 170 - 830 Cells/uL 6 - 11 Months 160 - 950 Cells/uL 12 - 23 Months 180 - 920 Cells/uL 2 - 5 Years 130 - 720 Cells/uL 6 - 11 Years 100 - 480 Cells/uL 12 - 17 Years 70 - 480 Cells/uL >/= 18 Years 74 - 562 Cells/uL | |||||
125 |
| 0 - 2 Months 6.0 - 32.0 % 3 - 5 Months 11.0 - 41.0 % 6 - 11 Months 14.0 - 37.0 % 12 - 23 Months 16.0 - 35.0 % 2 - 5 Years 14.0 - 33.0 % 6 - 11 Years 13.0 - 27.0 % 12 - 17 Years 6.0 - 23.0 % >/= 18 Years 5.7 - 24.9 % | |||||
126 |
| 0 - 2 Months 300 - 2000 Cells/uL 3 - 5 Months 430 - 3000 Cells/uL 6 - 11 Months 610 - 2600 Cells/uL 12 - 23 Months 720 - 2600 Cells/uL 2 - 5 Years 390 - 1400 Cells/uL 6 - 11 Years 270 - 860 Cells/uL 12 - 17 Years 110 - 570 Cells/uL >/= 18 Years 87 - 507 Cells/uL | |||||
127 | |||||||
128 |
| CSF: Nucleated Cells: 0 - 1 Year: 0-22 Cells/uL 1 - 12 Years: 0 - 7 Cells/uL > 12 Years: 0 - 5 Cells/uL RBCs: 0 - 2 Cells/uL BODY FLUID: Nucleated Cells: Synovial Fluids: 0-150 mm3 All Other Fluids: 0-500 mm3 | |||||
129 | |||||||
130 |
| Negative | |||||
131 | |||||||
132 |
| SERUM: 0 - 29 Days: 98 - 113 mmol/L >/= 30 Days: 98 - 107 mmol/L URINE: Random: No Reference Ranges Established Timed: Varies significantly with hydration and chloride intake. 0 - 27 Days: No Reference Ranges Established 28 Days - 23 Months: 2 - 10 mmol/24 hrs 2 - 17 Years: 15 - 40 mmol/24 hrs >/= 18 Years: 110 - 250 mmol/24 hrs | SERUM: 0 - 29 Days: 98 - 113 mmol/L >/= 30 Days: 98 - 107 mmol/L URINE: Random: No Reference Ranges Established Timed: Varies significantly with hydration and chloride intake. 0 - 27 Days: No Reference Ranges Established 28 Days - 23 Months: 2 - 10 mmol/24 hrs 2 - 17 Years: 15 - 40 mmol/24 hrs >/= 18 Years: 110 - 250 mmol/24 hrs | ||||
133 | |||||||
134 |
| 0 - 29 mmol/L Interpretive Data: </= 29 mmol/L - CF unlikely 30-59 mmol/L - Intermediate range, needs further study to establish or rule out a CF diagnosis. >/= 60 mmol/L - Indicative of CF for individuals presenting with a positive screen, clinical features consistent with CF, or a positive family history. | |||||
135 | |||||||
136 |
| Male: < 7.3 ng/mL Female: < 3.5 ng/mL | Male: < 7.7 ng/mL Female: < 4.3 ng/mL | ||||
137 | |||||||
138 |
| Negative | |||||
139 | |||||||
140 |
| 0 - 27 Days: 15 - 22 mmol/L 28 Days - 11 Months: 20 - 28 mmol/L >/= 1 Year: 20 - 30 mmol/L | 0 - 27 Days: 14 - 27 mmol/L 28 Days - 11 Months: 20 - 28 mmol/L >/= 1 Year: 22 - 29 mmol/L | ||||
141 | |||||||
142 |
| 0 - 11 Months: 50 - 160 mg/dL 1 - 13 Years: 80 - 173 mg/dL >/= 14 Years: 82 - 193 mg/dL | 0 - 11 Months: 50 - 160 mg/dL 1 - 13 Years: 80 - 173 mg/dL >/= 14 Years: 82 - 193 mg/dL | ||||
143 | |||||||
144 |
| 0 - 11 Months: 7 - 30 mg/dL 1 - 13 Years: 13 - 46 mg/dL >/= 14 Years: 15 - 57 mg/dL | 0 - 11 Months: 7 - 30 mg/dL 1 - 13 Years: 13 - 46 mg/dL >/= 14 Years: 15 - 57 mg/dL | ||||
145 | |||||||
146 |
| . | |||||
147 |
| Male: 0 - 14 Days 8.0 - 15.4 K/uL 15 - 30 Days 7.8 - 15.9 K/uL 31 - 60 Days 8.1 - 15.0 K/uL 2 - 5 Months 6.5 - 13.3 K/uL 6 - 23 Months 6.0 - 13.4 K/uL 2 - 5 Years 5.1 - 13.4 K/uL 6 - 11 Years 4.3 - 11.0 K/uL 12 - 17 Years 3.8 - 9.8 K/uL >/= 18 Years 3.5 - 10.8 K/uL Female: 0 - 14 Days 8.2 - 14.6 K/uL 15 - 30 Days 8.4 - 14.4 K/uL 31 - 60 Days 7.1 - 14.7 K/uL 2 - 5 Months 6.0 - 13.3 K/uL 6 - 23 Months 6.5 - 13.0 K/uL 2 - 5 Years 4.9 - 13.2 K/uL 6 - 11 Years 4.3 - 11.4 K/uL 12 - 17 Years 4.2 - 9.4 K/uL >/=18 Years 3.5 - 10.8 K/uL | |||||
148 |
| Male: 0 - 14 Days: 4.10 - 5.55 M/uL 15 - 30 Days: 3.16 - 4.63 M/uL 31 - 60 Days: 3.02 - 4.22 M/uL 2 - 5 Months: 3.43 - 4.80 M/uL 6 - 23 Months: 4.03 - 5.07 M/uL 2 - 5 Years: 3.89 - 4.97 M/uL 6 - 11 Years: 3.96 - 5.03 M/uL 12 - 17 Years: 4.03 - 5.29 M/uL >/= 18 Years: 4.17 - 5.89 M/uL Female: 0 - 14 Days: 4.12 - 5.74 M/uL 15 - 30 Days: 3.32 - 4.80 M/uL 31 - 60 Days: 2.93 - 3.87 M/uL 2 - 5 Months: 3.45 - 4.75 M/uL 6 - 23 Months: 3.97 - 5.01 M/uL 2 - 5 Years: 3.84 - 4.92 M/uL 6 - 11 Years: 3.90 - 4.96 M/uL 12 - 17 Years: 3.93 - 4.90 M/uL >/= 18 Years: 3.86 - 5.35 M/uL | |||||
149 |
| Male: 0 - 14 Days: 13.9 - 19.1 g/dL 15 - 30 Days: 10.0 - 15.3 g/dL 31 - 60 Days: 8.9 - 12.7 g/dL 2 - 5 Months: 9.6 - 12.4 g/dL 6 - 23 Months: 10.1 - 12.5 g/dL 2 - 5 Years: 10.2 - 12.7 g/dL 6 - 11 Years: 10.7 - 13.4 g/dL 12 - 17 Years: 11.0 - 14.5 g/dL >/= 18 Years: 12.7 - 17.2 g/dL Female: 0 - 14 Days: 13.4 - 20.0 g/dL 15 - 30 Days: 10.8 - 14.6 g/dL 31 - 60 Days: 9.2 - 11.4 g/dL 2 - 5 Months: 9.9 - 12.4 g/dL 6 Months - 5 Years: 10.2 - 12.7 g/dL 6 - 11 Years: 10.6 - 13.2 g/dL 12 - 17 Years: 10.8 - 13.3 g/dL >/= 18 Years: 11.0 - 15.4 g/dL | |||||
150 |
| Male: 0 - 14 Days: 39.8 - 53.6 % 15 - 30 Days: 30.5 - 45.0 % 31 - 60 Days: 26.8 - 37.5 % 2 - 5 Months: 28.6 - 37.2 % 6 - 23 Months:30.8 - 37.8 % 2 - 5 Years: 31.0 - 37.7 % 6 - 11 Years: 32.2 - 39.8 % 12 - 17 Years: 33.9 - 43.5 % >/= 18 Years: 39.4 - 51.6 % Female: 0 - 14 Days: 39.6 - 57.2 % 15 - 30 Days: 32.0 - 44.5 % 31 - 60 Days: 27.7 - 35.1 % 2 - 5 Months: 29.5 - 37.1 % 6 - 23 Months:30.9 - 37.9 % 2 - 5 Years: 31.2 - 37.8 % 6 - 11 Years: 32.4 - 39.5 % 12 - 17 Years: 33.4 - 40.4 % >/= 18 Years: 35.6 - 47.3 % | |||||
151 |
| Male: 0 - 14 Days: 91.3 - 103.1 fL 15 - 30 Days: 89.4 - 99.7 fL 31 - 60 Days: 84.3 - 94.2 fL 2 - 5 Months: 74.1 - 87.5 fL 6 - 23 Months:69.5 - 81.7 fL 2 - 5 Years: 71.3 - 84.0 fL 6 - 11 Years: 74.4 - 86.1 fL 12 - 17 Years: 76.7 - 89.2 fL >/= 18 Years: 79.0 - 100.0 fL Female: 0 - 14 Days: 92.7 - 106.4 fL 15 - 30 Days: 90.1 - 103.0 fL 31 - 60 Days: 83.4 - 96.4 fL 2 - 5 Months: 74.8 - 88.3 fL 6 - 23 Months:71.3 - 82.6 fL 2 - 5 Years: 72.3 - 85.0 fL 6 - 11 Years: 75.9 - 87.6 fL 12 - 17 Years: 76.9 - 90.6 fL >/= 18 Years: 79.0 - 100.0 fL | |||||
152 |
| Male: 0 - 14 Days: 31.3 - 35.6 pg 15 - 30 Days: 29.9 - 34.1 pg 31 - 60 Days: 27.8 - 32.0 pg 2 - 5 Months: 24.4 - 28.9 pg 6 - 23 Months:22.7 - 27.2 pg 2 - 5 Years: 23.7 - 28.3 pg 6 - 11 Years: 24.9 - 29.2 pg 12 - 17 Years: 25.2 - 30.2 pg >/= 18 Years: 25.7 - 33.2 pg Female: 0 - 14 Days: 31.1 - 35.9 pg 15 - 30 Days: 30.4 - 35.3 pg 31 - 60 Days: 28.0 - 32.5 pg 2 - 5 Months: 24.4 - 29.5 pg 6 - 23 Months:23.2 - 27.5 pg 2 - 5 Years: 23.7 - 28.6 pg 6 - 11 Years: 24.8 - 29.5 pg 12 - 17 Years: 24.8 - 30.2 pg >/= 18 Years: 23.7 - 32.9 pg | |||||
153 |
| Male: 0 - 14 Days: 33.0 - 35.7 g/dL 15 - 30 Days: 32.7 - 35.1 g/dL 31 - 60 Days: 32.3 - 34.8 g/dL 2 - 5 Months: 31.9 - 34.4 g/dL 6 - 23 Months:31.6 - 34.4 g/dL 2 - 5 Years: 32.0 - 34.7 g/dL 6 - 11 Years: 32.2 - 34.9 g/dL 12 - 17 Years: 31.8 - 34.8 g/dL >/= 18 Years: 30.0 - 36.5 g/dL Female: 0 - 14 Days: 33.4 - 35.4 g/dL 15 - 30 Days: 33.2 - 35.0 g/dL 31 -60 Days: 32.5 - 34.9 g/dL 2 - 5 Months: 32.1 - 34.4 g/dL 6 - 23 Months:31.9 - 34.2 g/dL 2 - 11 Years: 31.8 - 34.6 g/dL 12 - 17 Years: 31.5 - 34.2 g/dL >/= 18 Years: 30.0 - 36.5 g/dL | |||||
154 |
| Male: 0 - 14 Days: 14.8 - 17.0 % 15 - 30 Days: 14.3 - 16.8 % 31 - 60 Days: 13.8 - 16.1 % 2 - 5 Months: 12.4 - 15.3 % 6 - 23 Months:12.9 - 15.6 % 2 - 5 Years: 12.5 - 14.9 % 6 - 11 Years: 12.3 - 14.1 % 12 - 17 Years: 12.4 - 14.5 % >/= 18 Years: 11.6 - 16.0 % Female: 0 - 14 Days: 14.6 - 17.3 % 15 - 30 Days: 14.4 - 16.2 % 31 - 60 Days: 13.6 - 15.8 % 2 - 5 Months: 12.2 - 14.3 % 6 - 23 Months:12.7 - 15.1 % 2 - 5 Years: 12.4 - 14.9 % 6 - 11 Years: 12.2 - 14.4 % 12 - 17 Years: 12.3 - 14.6 % >/= 18 Years: 11.6 - 16.0 % | |||||
155 |
| Male: 0 - 14 Days: 51.0 - 61.7 fL 15 - 30 Days: 46.3 - 57.3 fL 31 - 60 Days: 43.9 - 52.8 fL 2 - 5 Months: 35.3 - 45.7 fL 6 - 23 Months:35.3 - 45.7 fL 2 - 5 Years: 35.3 - 42.8 fL 6 - 11 Years: 35.1 - 41.7 fL 12 - 17 Years: 36.7 - 43.8 fL >/= 18 Years: 35.1 - 43.9 fL Female: 0 - 14 Days: 51.4 - 65.7 fL 15 - 30 Days: 47.2 - 59.8 fL 31 - 60 Days: 43.0 - 55.0 fL 2 - 5 Months: 35.2 - 45.1 fL 6 - 23 Months:34.9 - 42.4 fL 2 - 5 Years: 34.9 - 42.0 fL 6 - 11 Years: 35.5 - 41.8 fL 12 - 17 Years: 37.1 - 44.2 fL >/= 18 Years: 36.4 - 46.3 fL | |||||
156 |
| Male: 0 - 14 Days: 10.2 - 11.9 fL 15 - 30 Days: 10.1 - 12.1 fL 31 - 60 Days: 9.2 - 10.8 fL 2 - 5 Months: 8.9 - 10.6 fL 6 - 23 Months:8.7 - 10.5 fL 2 - 5 Years: 9.0 - 10.9 fL 6 - 11 Years: 9.2 - 11.4 fL 12 - 17 Years: 9.6 - 11.8 fL >/= 18 Years: Sysmex: 9.2 - 12.8 fL Beckman: 6.9 - 10.6 fL Female: 0 - 14 Days: 10.4 - 12.0 fL 15 - 30 Days: 10.0 - 12.2 fL 31 - 60 Days: 9.4 - 11.1 fL 2 - 5 Months: 9.0 - 10.9 fL 6 - 23 Months: 8.8 - 10.6 fL 2 - 5 Years: 8.9 - 11.0 fL 6 - 11 Years: 9.3 - 11.3 fL 12 - 17 Years: 9.6 - 11.7 fL >/= 18 Years: Sysmex: 9.2 - 12.8 fL Beckman: 6.9 - 10.6 fL | |||||
157 |
| Male: 0 - 14 Days: 218 - 419 K/uL 15 - 30 Days: 248 - 586 K/uL 31 - 60 Days: 229 - 562 K/uL 2 - 5 Months: 244 - 529 K/uL 6 - 23 Months:206 - 445 K/uL 2 - 5 Years: 202 - 403 K/uL 6 - 11 Years: 206 - 369 K/uL 12 - 17 Years: 175 - 332 K/uL >/= 18 Years: 150 - 400 K/uL Female: 0 - 14 Days: 144 - 449 K/uL 15 - 30 Days: 279 - 571 K/uL 31 - 60 Days: 331 - 597 K/uL 2 - 5 Months: 247 - 580 K/uL 6 - 23 Months:214 - 459 K/uL 2 - 5 Years: 189 - 394 K/uL 6 - 11 Years: 199 - 367 K/uL 12 - 17 Years: 194 - 345 K/uL >/= 18 Years: 150 - 400 K/uL | |||||
158 |
| ABSOLUTE: 0 - 3 Days: 0.1 - 8.3 >/= 4 Days: 0.0 - 0.2 PERCENT: 0 - 3 Days: 0 - 8 % >/= 4 Days: 0 % | |||||
159 |
| . | |||||
160 |
| Male: 0 - 14 Days: 1.60 - 6.06 K/uL 15 - 30 Days: 1.18 - 5.45 K/uL 31 - 60 Days: 0.83 - 4.23 K/uL 61 - 180 Days:0.97 - 5.45 K/uL 6 - 23 Months:1.19 - 7.21 K/uL 2 - 5 Years: 1.54 - 7.92 K/uL 6 - 11 Years: 1.63 - 7.55 K/uL 12 - 17 Years: 1.54 - 7.04 K/uL >/= 18 Years: 1.78 - 5.38 K/uL Female: 0 - 14 Days: 1.73 - 6.75 K/uL 15 - 30 Days: 1.23 - 4.80 K/uL 31 - 60 Days: 1.00 - 4.68 K/uL 61 - 180 Days:1.04 - 7.20 K/uL 6 - 23 Months:1.27 - 7.18 K/uL 2 - 5 Years: 1.60 - 8.29 K/uL 6 - 11 Years: 1.64 - 7.87 K/uL 12 - 17 Years: 1.82 - 7.47 K/uL >/= 18 Years: 1.56 - 6.13 K/uL | |||||
161 |
| Male 0 - 14 Days: 2.07 - 7.53 K/uL 15 - 30 Days: 2.11 - 8.38 K/uL 31 - 60 Days: 2.47 - 7.95 K/uL 61 - 180 Days: 2.45 - 8.89 K/uL 6 - 23 Months: 1.56 - 7.83 K/uL 2 - 5 Years: 1.13 - 5.52 K/uL 6 - 11 Years: 0.97 - 3.96 K/uL 12 - 17 Years 0.97 - 3.26 K/uL >/= 18 Years: 1.32 - 3.57 K/uL Female 0 - 14 Days: 1.75 - 8.00 K/uL 15 - 30 Days: 2.42 - 8.20 K/uL 31 - 60 Days: 2.29 - 9.14 K/uL 61 - 180 Days: 2.14 - 8.99 K/uL 6 - 23 Months: 1.52 - 8.99 K/uL 2 - 5 Years: 1.25 - 5.77 K/uL 6 - 11 Years: 1.16 - 4.28 K/uL 12 - 17 Years: 1.16 - 3.33 K/uL >/= 18 Years: 1.18 - 3.74 K/uL | |||||
162 |
| Male: 0 - 14 Days: 0.52 - 1.77 K/uL 15 - 30 Days: 0.28 - 1.38 K/uL 31 - 60 Days: 0.28 - 1.05 K/uL 2 - 5 Months: 0.28 - 1.07 K/uL 6 - 23 Months: 0.25 - 1.15 K/uL 24 - 35 Months: 0.19 - 0.94 K/uL 3 - 5 Years: 0.30 - 0.90 K/uL 6 - 16 Years: 0.20 - 0.80 K/uL >/= 17 Years: 0.30 - 0.82 K/uL Female: 0 - 14 Days: 0.57 - 1.72 K/uL 15 - 30 Days: 0.42 - 1.21 K/uL 31 - 60 Days: 0.28 - 1.21 K/uL 2 - 5 Months: 0.24 - 1.17 K/uL 6 - 23 Months: 0.26 - 1.08 K/uL 24 - 35 Months: 0.24 - 0.92 K/uL 3 - 5 Years: 0.30 - 0.90 K/uL 6 - 16 Years: 0.20 - 0.80 K/uL >/= 17 Years: 0.24 - 0.86 K/uL | |||||
163 |
| Male: 0 - 14 Days: 0.12 - 0.66 K/uL 15 - 30 Days: 0.08 - 0.80 K/uL 31 - 60 Days: 0.05 - 0.57 K/uL 2 - 5 Months: 0.03 - 0.61 K/uL 6 - 23 Months: 0.02 - 0.82 K/uL 24 - 35 Months: 0.03 - 0.53 K/uL 3 - 11 Years: 0.00 - 0.50 K/uL 12 - 16 Years: 0.10 - 0.20 K/uL >/= 17 Years: 0.04 - 0.54 K/uL Female: 0 - 14 Days: 0.09 - 0.64 K/uL 15 - 30 Days: 0.06 - 0.75 K/uL 31 - 60 Days: 0.04 - 0.63 K/uL 2 - 5 Months: 0.02 - 0.74 K/uL 6 - 23 Months: 0.02 - 0.58 K/uL 24 - 35 Months: 0.03 - 0.46 K/uL 3 - 11 Years: 0.00 - 0.50 K/uL 12- 16 Years: 0.10 - 0.20 K/uL >/= 17 Years 0.04 - 0.36 K/uL | |||||
164 |
| Male: 0 - 14 Days: 0.02 - 0.11 K/uL 15 - 30 Days: 0.01 - 0.07 K/uL 2 - 35 Months: 0.01 - 0.06 K/uL 3 - 16 Years: 0.00 - 0.10 K/uL >/= 17 Years: 0.01 - 0.08 K/uL Female: 0 - 14 Days 0.02 - 0.07 K/uL 15 - 30 Days: 0.01 - 0.06 K/uL 31 - 60 Days: 0.01 - 0.05 K/uL 2 - 5 Months: 0.01 - 0.07 K/uL 6 - 35 Months: 0.01 - 0.06 K/uL 3 - 16 Years: 0.00 - 0.10 K/uL >/= 17 Years: 0.01 - 0.08 K/uL | |||||
165 |
| 0.00 - 0.03 K/uL | |||||
166 |
| 0% | |||||
167 | |||||||
168 |
| 0 - 14 Days: 0.5 - 12.3 ug/dL 15 Days - 11 Months: 0.5 - 16.6 ug/dL 1 - 8 Years: 1.7 - 10.8 ug/dL 9 - 13 Years: 2.2 - 12.7 ug/dL 14 - 16 Years: 2.8 - 16.4 ug/dL 17 - 19 Years: 3.5 - 18.3 ug/dL >/= 20 Years: Before 10 am 3.7 - 19.4 After 10 am 2.9 - 17.3 | 0 - 30 Days: 0.5 - 14.0 ug/dL 1 - 11 Months: 0.7 - 20.0 ug/dL 1 - 11 Years: 2.4 - 15.0 ug/dL 12 - 18 Years: 3.6 - 17.0 ug/dL >/= 19 Years: Morning hours (6 - 10 am): 4.8 - 19.5 ug/dL Afternoon hours (4 - 8 pm): 2.5 - 11.9 ug/dL | ||||
169 | |||||||
170 |
| > 20 ug/dL | > 20 ug/dL | ||||
171 | |||||||
172 | 09/06/22 |
| Negative | ||||
173 | 09/06/22 | ||||||
174 |
| Negative | |||||
175 | |||||||
176 |
| Negative | Negative | ||||
177 | |||||||
178 | 07/07/22 |
| 0.78 - 5.19 ng/mL | ||||
179 | 07/07/22 | ||||||
180 |
| INFLAMMATION: 0 - 12 Months </=15.2 1 - 6 Years: </=25.3 6 - 11 Years: </=11.8 11 - 15 Years: </=18.1 15 - 21 Years: </=24.2 >/= 21 Years: </=5.0 | INFLAMMATION: 0 - 12 Months: </= 15.2 1 - 6 Years: </= 25.3 6 - 11 Years: </= 11.8 11 - 15 Years: </= 18.1 15 - 21 Years: </= 24.2 >/= 21 Years: </= 5.0 | ||||
181 | |||||||
182 |
| SERUM: 0 - 14 Days: 0.42-1.05 mg/dL 15 Days - 11 Months:0.31-0.53 mg/dL 1 - 11 Years: 0.39-0.69 mg/dL 12 - 14 Years: 0.57-0.80 mg/dL 15 - 17 Years: Male :0.65-1.10 mg/dL Female: 0.59-0.88 mg/dL >/= 18 Years: Male: 0.72-1.25 mg/dL Female: 0.57-1.11 mg/dL URINE: Random: No Established Reference Range Timed/24 Hr: Male: 950 - 2490 mg/24 hours Female: 710 - 1650 mg/24 hours Timed Concentration: Male: 63 - 166 mg/dL Female: 47 - 110 mg/dL Clearance: Male: 66 - 163 mL/min/1.73 m2 Female: 66 - 165 mL/min/1.73 m2 24 hr Excretion (Output): 0 - 23 Months: 9.0-18.0 mg/kg/24 hr 2 - 12 Years: 18.0-24.0 mg/kg/24 hr 13 - 17 Years: Male: 27.0-30.0 mg/kg/24 hr Female: 18.0-24.0 mg/kg/24hr >/=18 Years: Male:12.1 - 28.9 mg/kg/24hr Female:10.7 - 26.0 mg/kg/24hr BODY FLUID: Pleural and Peritoneal: Urine extravasation will usually present as a transudate with a high concentration of creatinine and urea and a low concentration of glucose and pH. Peritoneal Fluid creatinine concentration will be markedly elevated (2.0-10.0 mg/dL), with the creatinine to serum creatinine greater than 1.0. In the situation in which fluid aspiration inadvertently consists of urine from the bladder, the urea to creatinine ratio should be much higher than for peritoneal fluid from which urea is more readily absorbed than creatinine. Leakage of urine should be suspected when the fluid has a high creatinine concentration relative to that in serum from a simultaneously collected blood specimen. | SERUM: 0 - 3 Days: 0.30 - 1.00 mg/dL 4 Days - 11 Months: 0.20 - 0.40 mg/dL 1 - 11 Years: 0.30 - 0.70 mg/dL 12 - 14 Years: 0.50 - 1.00 mg/dL 15 - 17 Years: Male: 0.65 - 1.10 mg/dL Female: 0.59 - 0.88 mg/dL >/= 18 Years: Male: 0.67 - 1.17 mg/dL Female: 0.51 - 0.95 mg/dL URINE: Random: No Established Reference Range Timed/24 Hr: Male: 980 - 2200 mg/24 hours Female: 720 - 1510 mg/24 hours Timed Concentration: Male: 40.00 - 278.00 mg/dL Female: 29.00 - 226.00 mg/dL Clearance: 66 - 143 mL/min/1.73 m2 24 hr Excretion (Output): 0 - 23 Months: 9.0 - 18.0 mg/kg/24 hr 2 - 12 Years: 18.0 - 24.0 mg/kg/24 hr 13 - 17 Years: Male: 27.0 - 30.0 mg/kg/24 hr Female: 18.0 - 24.0 mg/kg/24hr >/=18 Years: Male:12.1 - 28.9 mg/kg/24hr Female:10.7 - 26.0 mg/kg/24hr BODY FLUID: Pleural and Peritoneal: Urine extravasation will usually present as a transudate with a high concentration of creatinine and urea and a low concentration of glucose and pH. Peritoneal Fluid creatinine concentration will be markedly elevated (2.0-10.0 mg/dL), with the creatinine to serum creatinine greater than 1.0. In the situation in which fluid aspiration inadvertently consists of urine from the bladder, the urea to creatinine ratio should be much higher than for peritoneal fluid from which urea is more readily absorbed than creatinine. Leakage of urine should be suspected when the fluid has a high creatinine concentration relative to that in serum from a simultaneously collected blood specimen. | ||||
183 | |||||||
184 |
| Male: 30 - 200 U/L Female: 29 - 168 U/L | Male: 20 - 200 IU/L Female: 20 - 180 IU/L | ||||
185 | |||||||
186 |
| Negative | |||||
187 | |||||||
188 |
| Negative | |||||
189 | |||||||
190 |
| Absent | |||||
191 | |||||||
192 |
| No crystals identified | |||||
193 | |||||||
194 | 06/01/22 |
| 0.4 - 6.9 U/mL Interpretive Data: 0.4-6.9: Negative 7.0-10.0: Equivocal > 10.0: Positive | ||||
195 | |||||||
196 |
| Upstate: 100.0 - 200.0 ng/mL Midlands: 100 - 400 ng/mL Interpretive Data: Therapeutic ranges are poorly defined. They are related to clinical protocol, the organ transplanted, time following transplantation, organ function, and coadministration of other drugs. Ranges are also method and specimen dependent. | 100 - 400 ng/mL | ||||
197 | |||||||
198 | 07/11/22 |
| Negative | ||||
199 | 07/11/22 | ||||||
200 | 07/11/22 |
| Negative | ||||
201 | 07/11/22 | ||||||
202 |
| < 0.50 ug/mL Interpretive Data: For Outpatients with a value of less than 0.50 ug/ml FEU and with low to moderate clinical pretest probability, this method is FDA cleared to exclude pulmonary emoblism (PE) and as an aid in the diagnosis of deep venous thrombosis (DVT). | |||||
203 | |||||||
204 | 09/06/22 |
| Male: 11 Years - 14 Years: 26.0 - 380.0 ug/dL 15 Years - 20 Years: 86.0 - 634.0 ug/dL 21 Years - 24 Years: 238.4 - 539.3 ug/dL 25 Years - 34 Years: 167.9 - 591.9 ug/dL 35 Years - 44 Years: 139.7 - 484.4 ug/dL 45 Years - 54 Years: 136.2 - 447.6 ug/dL 55 Years - 64 Years: 48.6 - 361.8 ug/dL 65 Years - 69 Years: 228.5 - 283.6 ug/dL >/= 70 Years 34.5 - 568.9 ug/dL Female: 11 Years - 14 Years: 26.0 - 380.0 ug/dL 15 Years - 20 Years: 50.0 - 459.0 ug/dL 21 Years - 24 Years: 134.2 - 407.4 ug/dL 25 Years - 34 Years: 95.8 - 511.7 ug/dL 35 Years - 44 Years: 74.8 - 410.2 ug/dL 45 Years - 54 Years: 56.2 - 282.9 ug/dL 55 Years - 64 Years: 29.7 - 182.2 ug/dL 65 Years - 69 Years: 33.6 - 78.9 ug/dL >/= 70 Years 25.9 - 460.2 ug/dL | ||||
205 | 09/06/22 | ||||||
206 |
| 0.8 - 2.0 ng/mL | 0.8 - 2.0 ng/mL | ||||
207 | |||||||
208 |
| Total: 10.0 - 20.0 ug/mL Free: 1.0 - 2.0 ug/mL Free %: 10 - 20% | Total: 10.0 - 20.0 ug/mL Free: 1.0 - 2.0 ug/mL Free %: 10 - 20% | ||||
209 | |||||||
210 | 09/07/22 |
| No evidence of phospholipid inhibitor | ||||
211 | 09/07/22 | ||||||
212 |
| . | |||||
213 | 07/07/22 |
| Negative (cutoff 40 ng/mL) | ||||
214 |
| Negative (cutoff 500 ng/mL) | Negative (cutoff 500 ng/mL) | ||||
215 |
| Negative (cutoff 200 ng/mL) | Negative (cutoff 200 ng/mL) | ||||
216 |
| Negative (cutoff 200 ng/mL) | Negative (cutoff 200 ng/mL) | ||||
217 |
| Negative (cutoff 5 ng/mL) | Negative (cutoff 5 ng/mL) | ||||
218 |
| Negative (cutoff 50 ng/mL) | Negative (cutoff 50 ng/mL) | ||||
219 |
| Negative (cutoff 150 ng/mL) | Negative (cutoff 150 ng/mL) | ||||
220 | 07/07/22 |
| Negative (cutoff 2000 ng/mL) | ||||
221 |
| Negative (cutoff 500 ng/mL) | Negative (cutoff 500 ng/mL) | ||||
222 | 07/07/22 |
| Negative (cutoff 500 ng/mL) | ||||
223 |
| Negative (cutoff 300 ng/mL) | Negative (cutoff 300 ng/mL) | ||||
224 | 07/07/22 |
| Negative (cutoff 2000 ng/mL) | ||||
225 |
| Negative (cutoff 300 ng/mL) | Negative (cutoff 300 ng/mL) | ||||
226 |
| Negative (cutoff 100 ng/mL) | Negative (cutoff 100 ng/mL) | ||||
227 |
| Negative (cutoff 25 ng/mL) | |||||
228 |
| Negative (cutoff 200 ng/mL) | Negative (cutoff 200 ng/mL) | ||||
229 | 07/07/22 |
| Negative (cutoff 300 ng/mL) | ||||
230 |
| Negative (cutoff 1 ng/mL) | Negative (cutoff 1 ng/mL) | ||||
231 | |||||||
232 | 07/11/22 |
| Negative | ||||
233 | 07/11/22 | ||||||
234 | 07/11/22 |
| Negative | ||||
235 | 07/11/22 | ||||||
236 |
| ESR PLUS: Male: 0 - 49 Years: 0-15 mm/hr 50 - 84 Years: 0-20 mm/hr >/= 85 Years: 0-30 mm/hr Female: 0 - 49 Years: 0-20 mm/hr 50 - 84 Years: 0-30 mm/hr >/= 85 Years: 0-42 mm/hr ISED: Male: 0 - 11 Months: 0 - 2 mm/hr 1 - 11 Years: 3 - 13 mm/hr 12 - 49 Years: 0 - 15 mm/hr >/= 50 Years: 0 - 20 mm/hr Female: 0 - 11 Months: 0 - 2 mm/hr 1 - 11 Years: 3 - 13 mm/hr 12 - 49 Years: 0 - 20 mm/hr >/= 50 Years: 0 - 30 mm/hr | |||||
237 | |||||||
238 |
| Male: 11 - 44 pg/mL Female: Pre-pubertal: < 20 pg/mL Follicular phase: 21-251 pg/mL Mid-cycle: 38-649 pg/mL Luteal Phase: 21-312 pg/mL Postmenopausal: <29 pg/mL Postmenopausal on HRT: <145 pg/mL | Male: 11 - 43 pg/mL Female: Estradiol, Follicular: 31 - 90 pg/mL Estradiol, Ovulation: 60 - 533 pg/mL Estradiol, Luteal: 60 - 232 pg/mL Estradiol, Postmenopausal: < 5 - 138 pg/mL Estradiol, 1st trimester: 154 - 3243 pg/mL Estradiol, 2nd Trimester: 1561 - 21280 pg/mL Estradiol, 3rd Trimester: 8525 - >30000 pg/mL | ||||
239 | |||||||
240 |
| . | |||||
241 | 09/07/22 |
| 70-120 % | ||||
242 | 09/07/22 |
| 70-120 % | ||||
243 | 09/07/22 |
| 55-170 % | ||||
244 |
| 60-150 % | |||||
245 |
| 60-150 % | |||||
246 | 09/07/22 |
| 70-120 % | ||||
247 | 09/07/22 |
| 60-150 % | ||||
248 |
| > 49 % | |||||
249 | |||||||
250 |
| Negative* *Small amount of neutral fat is normal. | |||||
251 | |||||||
252 |
| Negative | |||||
253 | |||||||
254 |
| Negative | |||||
255 | |||||||
256 |
| 0 - 4 Days: No reference range established 4 - 14 Days: 100.0 - 717.0 ng/mL 15 - 180 Days: 14.0 - 647.0 ng/mL 6 - 11 Months: 8.0 - 182.0 ng/mL 1 - 4 Years: 5.0 - 100.0 ng/mL 5 - 13 Years: 14.0 - 79.0 ng/mL 14 - 15 Years: Male: 13.0 - 83.0 ng/mL Female: 6.0 - 67.0 ng/mL 16 - 19 Years: Male: 11.0 - 172.0 ng/mL Female: 6.0 - 67.0 ng/mL >/= 20 Years: Male: 22.0 - 275.0 ng/mL Female: 5.0 - 204.0 ng/mL | 0 - 30 Days: 150.0 - 973.0 ng/mL 1 - 5 Months: 8.5 - 580.0 ng/mL 6 Months - 14 Years: 14.0 - 101.0 ng/mL 15 - 19 Years: Male: 20.9 - 173.0 ng/mL Female: 3.9 - 114.0 ng/mL >/=20 Years: Male: 30.0 - 400.0 ng/mL Female: 13.0 - 150.0 ng/mL | ||||
257 | |||||||
258 |
| Negative | |||||
259 | |||||||
260 |
| < 0 % | |||||
261 | |||||||
262 |
| < 5 ug/mL | |||||
263 | |||||||
264 |
| 240 - 490 mg/dL | |||||
265 | |||||||
266 |
| 7.0 - 31.4 ng/mL | 4.8 - 24.2 ng/mL | ||||
267 | |||||||
268 |
| Male: 1 - 11 Months: 0.1 - 2.4 mIU/mL 1 - 4 Years: 0.0 - 0.9 mIU/mL 5 - 9 Years: 0.0 - 1.6 mIU/mL 10 - 12 Years: 0.4 - 3.9 mIU/mL 13 - 18 Years: 0.8 - 5.1 mIU/mL >/= 19 Years: 1.0 - 12.0 mIU/mL Female: 1 - 11 Months: 0.4 - 10.4 mIU/mL 1 - 8 Years: 0.4 - 5.5 mIU/mL 9 - 10 Years: 0.4 - 4.2 mIU/mL 11 - 18 Years: 0.3 - 7.8 mIU/mL >/= 18 Years: Normally Menstruating Females: Follicular Phase: 3.0 - 8.1 mIU/mL Mid-Cycle: 2.6 - 16.7 mIU/mL Luteal: 1.4 - 5.5 mIU/mL Post Menopausal: 26.8 - 133.4 mIU/mL | Male: 0 - 11 Months: 0.1 - 3.2 mIU/mL 1 - 8 Years: 0.2 - 2.1 mIU/mL 9 - 11 Years: 0.4 - 4.2 mIU/mL 12 - 18 Years: 0.9 - 7.1 mIU/mL >/= 19 Years: 1.5 - 12.4 mIU/mL Female: 0 - 11 Months: 1.6 - 19.0 mIU/mL 1 - 8 Years: 0.7 - 5.8 mIU/mL 9 - 11 Years: 0.5 - 7.6 mIU/mL 12 - 18 Years: 0.9 - 9.1 mIU/mL >/= 19 Years: 1.5 - 12.4 mIU/mL | ||||
269 | |||||||
270 |
| <1.0% is indicative of prerenal azotemia. >1.5% is indicative of acute tubular necrosis. | <1.0% is indicative of prerenal azotemia. >1.5% is indicative of acute tubular necrosis. | ||||
271 | |||||||
272 |
| Normal | |||||
273 | |||||||
274 |
| Male: 12 - 64 IU/L Female: 9 - 36 IU/L | Male: 8 - 61 IU/L Female: 5 - 36 IU/L | ||||
275 | |||||||
276 |
| TROUGH: 0 - 2 Months < 1.1 ug/mL >/= 3 Months < 2.0 ug/mL PEAK: 5.0 - 10.0 ug/mL RANDOM: 2.0 - 10.0 ug/mL | TROUGH: 0 - 2 Months: < 1.1 ug/mL >/= 3 Months: < 2.0 ug/mL PEAK: 5.0 - 10.0 ug/mL RANDOM: 2.0 - 10.0 ug/mL | ||||
277 | |||||||
278 |
| Not Detected | |||||
279 | |||||||
280 |
| Negative | |||||
281 | |||||||
282 |
| >/= 2 Years: > 59 mL/min/1.73 m2* *Interpret with caution, quantification of eGFR values below 60 mL/min/1.73 sq meter has more clinical implications for classification of kidney function than values above this level. GFR and GFRA are calculated using the CKD-EPI equation for >18 Years and Bedside Schwartz for 2-18 Years. | >/= 2 Years: > 59 mL/min/1.73 m2* *Interpret with caution, quantification of eGFR values below 60 mL/min/1.73 sq meter has more clinical implications for classification of kidney function than values above this level. GFR and GFRA are calculated using the CKD-EPI equation for >18 Years and Bedside Schwartz for 2-18 Years. | ||||
283 | |||||||
284 | 06/20/22 |
| < 7.0 U/mL Interpretive Data: Negative 0.1-6.9 U/mL Equivocal 7.0-10.0 U/mL Positive >10.0 U/mL | ||||
285 | |||||||
286 | 06/20/22 |
| < 7.0 U/mL Interpretive Data: Negative 0.4-6.9 U/mL Equivocal 7.0-10.0 U/mL Positive >10.0 U/mL | ||||
287 | |||||||
288 | 06/01/22 |
| < 7.0 U/mL Normal < 7.0 U/mL Equivocal 7.0-10.0 U/mL Positive > 10.0 U/mL | ||||
289 | |||||||
290 |
| . | |||||
291 |
| NICU Inpatient Locations: 51 - 60 mg/dL 0 - 23 Hours: 40 - 60 mg/dL 1 Day - 11 Months: 54 - 80 mg/dL >/= 1 Year: 70 - 99 mg/dL Interpretive Data: Fasting Glucose: Impaired Fasting 100 - 125 mg/dL Diagnostic of Diabetes Mellitus >/= 126 mg/dL Random Glucose: Reference: 70 - 139 mg/dL Diagnostic of Diabetes Mellitus >/= 200 mg/dL | NICU Inpatient Locations: 51 - 60 mg/dL 0 - 23 Hours: 40 - 60 mg/dL 1 Day - 11 Months: 54 - 80 mg/dL >/= 1 Year: 70 - 99 mg/dL Interpretive Data: Fasting Glucose: Impaired Fasting 100 - 125 mg/dL Diagnostic of Diabetes Mellitus >/= 126 mg/dL Random Glucose: Reference: 70 - 139 mg/dL Diagnostic of Diabetes Mellitus >/= 200 mg/dL | ||||
292 |
| < 180 for Non-Pregnant Adults with Diabetes </= 120 for Women with GDM | < 180 mg/dL for Non-Pregnant Adults with Diabetes </= 120 mg/dL for Women with GDM | ||||
293 |
| Fasting: 70 - 99 mg/dL Interpretive Data: 70-99 Normal 100 - 125 Increased risk for Diabetes >/= 126 Provisional Diagnosis of Diabetes 2 Hour: 70 - 139 mg/dL Interpretive Data: 70-139 Normal 140-199 Increased risk for Diabetes >/= 200 Provisional Diagnosis of Diabetes | Fasting: 70 - 99 mg/dL Interpretive Data: 70-99 mg/dL Normal 100 - 125 mg/dL Increased risk for Diabetes >/= 126 mg/dL Provisional Diagnosis of Diabetes 2 Hour: 70 - 139 mg/dL Interpretive Data: 70-139 mg/dL Normal 140-199 mg/dL Increased risk for Diabetes >/= 200 mg/dL Provisional Diagnosis of Diabetes | ||||
294 |
| 70 - 139 mg/dL | 70 - 139 mg/dL | ||||
295 |
| The diagnosis of Gestational Diabetes Mellitus is made if at least two of the following four plasma glucose levels are met or exceeded: Fasting: < 95 mg/dL 1 Hour: < 180 mg/dL 2 Hour: < 155 mg/dL 3 Hour: < 140 mg/dL | The diagnosis of Gestational Diabetes Mellitus is made if at least two of the following four plasma glucose levels are met or exceeded: Fasting: < 95 mg/dL 1 Hour: < 180 mg/dL 2 Hour: < 155 mg/dL 3 Hour: < 140 mg/dL | ||||
296 |
| 0-10 Years: 60-80 mg/dL >/= 11 Years: 40-70 mg/dL | 0 - 10 Years: 60-80 mg/dL >/= 11 Years: 40-70 mg/dL | ||||
297 |
| < 60 mg/dL is suggestive of an empyema or parapneumonic effusion. | < 60 mg/dL is suggestive of an empyema or parapneumonic effusion. | ||||
298 |
| Refer to Glucose | Refer to Glucose | ||||
299 | |||||||
300 |
| Negative | |||||
301 | |||||||
302 |
| 0 - 14 Days: < 10 mg/dL 15 Days - 23 Months: 7 - 221 mg/dL 1 - 17 Years: 7 - 179 mg/dL 18 - 60 Years: Male: 14 - 258 mg/dL Female: 35 - 250 mg/dL >/= 61 Years: Male: 40 - 268 mg/dL Female: 63 - 273 mg/dL | 0 - 14 Days: </= 12 mg/dL 15 Days - 11 Months: </= 238 mg/dL 1 - 11 Years: </= 176 mg/dL 12 - 18 Years: </= 193 mg/dL >/= 19 Years: 30 - 200 mg/dL | ||||
303 | |||||||
304 |
| < 5.7 % Interpretive Data: 5.7 – 6.4% At Risk for Diabetes Mellitus If HbA1C results are not consistent with blood glucose monitoring results, interference should be considered. >/= 6.5% Diagnostic for Diabetes Mellitus. For monitoring diabetic patients, it is recommended that glycemic goals are individualized following current American Diabetes Association (ADA) Standards of Care recommendations. | < 5.7 % Interpretive Data: 5.7 – 6.4 % At Risk for Diabetes Mellitus If HbA1C results are not consistent with blood glucose monitoring results, interference should be considered. >/= 6.5 % Diagnostic for Diabetes Mellitus. For monitoring diabetic patients, it is recommended that glycemic goals are individualized following current American Diabetes Association (ADA) Standards of Care recommendations. | ||||
305 | |||||||
306 |
| Hgb A1: 96.0 - 98.0 % Hgb A2: 1.5 - 4.0 % Hgb S: 0.0 % Hgb C: 0.0 % Other Hgb 1: 0.0 % Hgb F: 0 - 6 Days: 77.0 - 97.0 % 7 - 14 Days: 79.6 - 91.4 % 15 - 45 Days: 59.8 - 89.6 % 46 Days - 2 Months: 23.9 - 67.2 % 3 - 5 Months: 4.4 - 27.5 % 6 - 8 Months: 1.5 - 27.8 % 9 - 14 Months: 0.4 - 8.4 % 15 - 23 Months: 0.1 - 4.9 % 2 - 5 Years: 0.0 - 3.7 % 6 - 17 Years: 0.0 - 1.3 % >/= 18 Years: 0.0 % | |||||
307 | |||||||
308 |
| Absent | |||||
309 | |||||||
310 |
| Non-Reactive | Non-Reactive | ||||
311 | |||||||
312 |
| < 8.00 mIU/mL: Non-Reactive - Individual is considered not immune to HBV infection. >/= 8.00 to < 12.00 mIU/mL: Gray Zone - The immune status of the individual should be further assessed by considering other factors, such as clinical status, follow-up testing, associated risk factors, and the use of additional diagnostic information. >/= 12.00 mIU/mL: Reactive - Individual is considered immune to HBV infection. | < 8.5 mIU/mL: Negative - Individual is considered to be not immune to infection with HBV. >/= 8.5 to < 11.5 mIU/mL: Indeterminate - Unable to determine if anti-HBs is present at levels consistent with immunity. >/= 11.5 mIU/mL: Positive - Anti HBs concentration detected at > 10 mIU/mL. Individual is considered to be immune to infection with HBV. | ||||
313 | |||||||
314 |
| Non-Reactive | Non-Reactive | ||||
315 | |||||||
316 |
| Non-Reactive | Non-Reactive | ||||
317 | |||||||
318 | 07/07/22 |
| Non-Reactive | ||||
319 | 07/07/22 | ||||||
320 |
| Non-Reactive | Non-Reactive | ||||
321 | |||||||
322 |
| Not Detected | |||||
323 | |||||||
324 |
| Not Detected | |||||
325 | |||||||
326 | 07/11/22 |
| Negative | ||||
327 | 07/11/22 | ||||||
328 | 07/11/22 |
| Negative | ||||
329 | 07/11/22 | ||||||
330 | 07/05/22 |
| Negative | ||||
331 | |||||||
332 |
| Non-Reactive | Non-Reactive | ||||
333 | |||||||
334 |
| Non-Reactive | Non-Reactive | ||||
335 | |||||||
336 |
| Non-Reactive | Non-Reactive | ||||
337 | |||||||
338 |
| Less than Limit of Dectection | |||||
339 | |||||||
340 | 07/07/22 |
| Male: 5.5 - 16.2 umol/L Female: 4.4 - 13.6 umol/L | ||||
341 | 07/07/22 | ||||||
342 |
| Negative | |||||
343 | |||||||
344 |
| 1.1 - 6.1 % | |||||
345 | |||||||
346 |
| 0 - 11 Months: 1 - 29 mg/dL 1 - 2 Years: 4 - 90 mg/dL 3 - 5 Years: 26 - 147 mg/dL 6 - 13 Years: 47 - 221 mg/dL 14 - 18 Years: 53 - 287 mg/dL 19 - 59 Years: Male: 63 - 484 mg/dL Female: 65 - 421 mg/dL >/= 60 Years: Male: 101 - 645 mg/dL Female: 69 - 517 mg/dL | |||||
347 | |||||||
348 | 06/20/22 |
| 0 - 5 Months: <14 kU/L 6 - 11 Months: < 35 kU/L 1 - 2 Years: < 98 kU/L 3 - 3 Years: < 200 kU/L 4 - 6 Years: < 308 kU/L 7 - 8 Years: < 404 kU/L 9 - 12 Years: < 697 kU/L 13 - 15 Years: < 630 kU/L 16 - 17 Years: < 538 kU/L >/=18 Years: < 215 kU/L | ||||
349 | |||||||
350 |
| 0 - 14 Days: 320 - 1407 mg/dL 15 Days - 11 Months: 109 - 702 mg/dL 1 - 3 Years: 316 - 1148 mg/dL 4 - 9 Years: 542 - 1358 mg/dL 10 - 19 Years: 658 - 1534 mg/dL >/=20 Years: Male: 540 - 1822 mg/dL Female: 552 - 1631 mg/dL | 0 - 14 Days: 320 - 1210 mg/dL 15 Days - 11 Months: 150 - 630 mg/dL 1 - 3 Years: 320 - 990 mg/dL 4 - 9 Years: 500 - 1170 mg/dL 10 - 18 Years: 600 - 1310 mg/dL >/=19 Years: 700 - 1600 mg/dL | ||||
351 | |||||||
352 |
| 0 - 14 Days: 5 - 35 mg/dL 15 Days - 2 Months 12 - 71 mg/dL 3 - 11 Months: 16 - 86 mg/dL 1 - 18 Years: Male: 39 - 151 mg/dL Female: 48 - 186 mg/dL >/= 19 Years: Male: 22 - 240 mg/dL Female: 33 - 293 mg/dL | |||||
353 | |||||||
354 |
| Negative | |||||
355 | |||||||
356 |
| Negative | |||||
357 | |||||||
358 |
| Negative | |||||
359 | |||||||
360 | 07/07/22 |
| 3.0 - 19.0 uU/mL | ||||
361 | 07/07/22 | ||||||
362 |
| 0 - 13 Years 16 - 128 ug/dL >/= 14 Years: Male: 65 - 175 ug/dL Female: 50 - 170 ug/dL | Female: 0 - 13 Years: 29 - 137 ug/dL 14 - 18 Years: 33 - 170 ug/dL >/= 19 Years: 37 - 145 ug/dL Male: 0 - 13 Years: 29 - 137 ug/dL 14 - 18 Years: 43 - 176 ug/dL >/= 19 Years: 61 - 157 ug/dL | ||||
363 | |||||||
364 |
| 0 - 62 Days: 130 - 280 ug/dL 63 Days - 11 Months: 134 - 405 ug/dL 1 - 59 Years: Male: 218 - 455 ug/dL Female: 225 - 478 ug/dL >/= 60 Years: Male: 204 - 569 ug/dL Female: 216 - 450 ug/dL | 0 - 56 Days: 139 - 304 ug/dL 57 Days - 11 Months: 144 - 440 ug/dL 1 - 17 Years: 298 - 458 ug/dL >/= 18 Years: 250 - 450 ug/dL | ||||
365 | |||||||
366 |
| </= 0.10 | |||||
367 | |||||||
368 |
| SERUM: 0 - 14 Days: 309 - 1222 IU/L 15 Days - 11 Months: 163 - 452 IU/L 1 - 9 Years: 192 - 321 IU/L 10 - 14 Years: Male: 170 - 283 IU/L Female: 157 - 272 IU/L 15 - 18 Years: 130 - 250 IU/L >/= 19 Years: 125 - 220 IU/L BODY FLUID: Interpretive Data: Ratio of Pleural Fluid LDH to a simultaneously collected Serum Protein >0.6 is predictive of an exudate. | 0 - 14 Days: </= 1128 IU/L 15 Days - 11 Months: </= 424 IU/L 1 - 9 Years: </= 305 IU/L 10 - 14 Years: Male: </= 270 IU/L Female: </= 260 IU/L 15 - 18 Years: </= 240 IU/L >/= 19 Years: Male: 135 - 225 IU/L Female: 135 - 214 IU/L BODY FLUID: Interpretive Data: Ratio of Pleural Fluid LDH to a simultaneously collected Serum Protein >0.6 is predictive of an exudate. | ||||
369 | |||||||
370 |
| PLASMA: 0.5 - 2.2 mmol/L CSF: 0.6 - 2.2 mmol/L | PLASMA: 0.5 - 2.2 mmol/L CSF: 0 - 2 Days: 1.1 - 6.7 mmol/L 3 - 10 Days: 1.1 - 4.4 mmol/L 11 Days - 18 Years: 1.1 - 2.8 mmol/L >/= 19 Years: 1.1 - 2.4 mmol/L | ||||
371 | |||||||
372 |
| Negative | |||||
373 | |||||||
374 |
| 5.0 - 45.0 ug/mL | 5.0 - 45.0 ug/mL | ||||
375 | |||||||
376 |
| 0 - 18 Years: 0 - 39 IU/L >/= 19 Years: 8 - 78 IU/L | 0 - 18 Years: </= 39 IU/L >/= 19 Years: 13 - 60 IU/L | ||||
377 | |||||||
378 |
| Negative | |||||
379 | |||||||
380 |
| Refer to ACC/AHA Clinical Practice Guidelines | Refer to ACC/AHA Clinical Practice Guidelines | ||||
381 |
| 0 - 14 Days: 42 - 125 mg/dL 15 Days - 11 Months: 64 - 237 mg/dL 1 - 9 Years: 112 - 208 mg/dL 10 - 19 Years: Acceptable < 170 mg/dL Borderline 170 - 199 mg/dL Abnormal >/=200 mg/dL >/= 20 Years: Desirable: < 200 mg/dL Borderline High: 200-239 mg/dL High: >/= 240 mg/dL | 0 - 14 Days: Male: 44 - 109 mg/dL Female: 48 - 125 mg/dL 15 Days - 11 Months: 66 - 234 mg/dL 1 - 9 Years: 112 - 207 mg/dL 10 - 19 Years: < 170 mg/dL >/= 20 Years: < 200 mg/dL | ||||
382 |
| < 3.5 | < 3.5 | ||||
383 |
| 0 - 15 Days: 15 - 42 mg/dL 15 Days - 1 Year: 12 - 71 mg/dL 1 - 10 Years: 32 - 73 mg/dL 10 - 19 Years: Acceptable: > 45 mg/dL Borderline: 40 - 45 mg/dL Abnormal: < 40 mg/dL >/= 20 Years: Optimal: >/= 60 mg/dL Borderline: 40 - 59 mg/dL Major Risk Factor: < 40 mg/dL | 0 - 14 Days: 7 - 39 mg/dL 15 Days - 11 Months: </=75 mg/dL 1 - 3 Years: 28 - 65 mg/dL 4 - 9 Years: 31 - 77 mg/dL 10 - 19 Years: Acceptable: > 45 mg/dL Borderline: 40 - 45 mg/dL Abnormal: < 40 mg/dL >/= 20 Years: Optimal: >/= 60 mg/dL Borderline: 40 - 59 mg/dL Major Risk Factor: < 40 mg/dL | ||||
384 |
| 0 - 11 Months: 13 - 173 mg/dL 1 - 9 Years: 47 - 128 mg/dL 10 - 19 Years: Acceptable: < 110 mg/dL Borderline: 110 - 129 mg/dL High: >/=130 mg/dL >/=20 Years: Desirable: <130 mg/dL Borderline: 130 - 159 mg/dL High Risk: >/=160 mg/dL | 0 - 11 Months: 13 - 173 mg/dL 1 - 9 Years: 47 - 128 mg/dL 10 - 19 Years: Acceptable: < 110 mg/dL Borderline: 110 - 129 mg/dL High: >/=130 mg/dL >/=20 Years: Desirable: <130 mg/dL Borderline: 130 - 159 mg/dL | ||||
385 |
| 0 - 11 Months: 28 - 202 mg/dL 1 - 9 Years: 69 - 166 mg/dL 10 - 19 Years: Acceptable: < 120 mg/dL Borderline: 120 - 144 mg/dL High: >/= 145 mg/dL >/= 20 Years: Optimal: < 130 mg/dL Borderline High: 130 - 159 mg/dL High: 160 - 189 mg/dL Very High: > 190 mg/dL | 0 - 11 Months: 28 - 202 mg/dL 1 - 9 Years: 69 - 166 mg/dL 10 - 19 Years: Acceptable: < 120 mg/dL Borderline: 120 - 144 mg/dL High: >/= 145 mg/dL >/= 20 Years: Optimal: < 130 mg/dL Borderline High: 130 - 159 mg/dL High: 160 - 189 mg/dL Very High: > 190 mg/dL | ||||
386 |
| 0 - 9 Years: Acceptable < 75 mg/dL Borderline 75 - 99 mg/dL Abnormal: >/= 100 mg/dL 10 - 19 Years: Acceptable: < 90 mg/dL Borderline: 90 - 129 mg/dL Abnormal: >/= 130 mg/dL >/= 20 Years: Acceptable: < 150 mg/dL Borderline: 150 - 199 mg/dL High: 200 - 499 mg/dL Very High: >/= 500 mg/dL | 0 - 9 Years: Acceptable < 75 mg/dL Borderline 75 - 99 mg/dL Abnormal: >/= 100 mg/dL 10 - 19 Years: Acceptable: < 90 mg/dL Borderline: 90 - 129 mg/dL Abnormal: >/= 130 mg/dL >/= 20 Years: Acceptable: < 150 mg/dL Borderline: 150 - 199 mg/dL High: 200 - 499 mg/dL Very High: >/= 500 mg/dL | ||||
387 |
| < 40 mg/dL | < 40 mg/dL | ||||
388 | |||||||
389 |
| 0.6 - 1.2 mmol/L | 0.6 - 1.2 mmol/L | ||||
390 | |||||||
391 |
| Once daily dosing: 1.00 - 2.00 IU/mL Twice daily dosing: 0.60 - 1.00 IU/mL Prophylactic range: 0.20 - 0.50 IU/mL | |||||
392 | |||||||
393 |
| Female: 4 Days - 2 Months: 0.0 - 2.4 mIU/mL 3 - 11 Months: 0.0 - 1.2 mIU/mL 1 - 9 Years: 0.0 - 0.3 mIU/mL 10 - 12 Years: 0.0 - 4.3 mIU/mL 13 - 14 Years: 0.4 - 6.5 mIU/mL 15 - 16 Years: 0.0 - 13.1 mIU/mL 17 - 18 Years: 0.0 - 8.4 mIU/mL Interpretive Data: Normal Menstruating Females: Follicular Phase: 1.8 - 11.8 mIU/mL Mid-Cycle Peak: 7.6 - 89.1 mIU/mL Luteal Cycle: 0.6 - 14.0 mIU/mL Postmenopausal without Hormone Therapy: 5.16 - 61.99 mIU/mL Male: 4 Days - 2 Months: 0.2 - 3.8 mIU/mL 3 - 1 Months: 0.0 - 2.9 mIU/mL 1 - 9 Years: 0.0 - 0.3 mIU/mL 10 - 12 Years: 0.0 - 4.3 mIU/mL 13 - 14 Years: 0.0 - 4.1 mIU/mL 15 - 16 Years: 0.8 - 4.8 mIU/mL 17 - 18 Years: 0.9 - 7.1 mIU/mL >/= 19 Years: 0.6 - 12.1 mIU/mL | Male: 0 - 5 Months: </= 6.2 mIU/mL 6 Months - 10 Years: </= 1.3 mIU/mL 11 - 13 Years: </= 2 mIU/mL 14 - 18 Years: 1.3 - 8.4 mIU/mL >/= 19 Years: 1.7 - 8.6 mIU/mL Female: 0 - 5 Months: </=8.2 mIU/mL 6 Months - 10 Years: </=1.3 mIU/mL 11 - 13 Years: </=10 mIU/mL 14 - 18 Years: 0.4-25 mIU/mL >/= 19 Years: Mid-Cycle/Ovulation: 14 - 95.6 mIU/mL Luteal: 1 - 11.4 mIU/mL Postmenopausal (w/o Hormone Therapy): 7.7 - 58.5 mIU/mL | ||||
394 | |||||||
395 |
| 0 - 20 Years: 1.5 - 2.3 mg/dL >/= 21 Years: 1.6 - 2.6 mg/dL | 0 - 20 Years: 1.5 - 2.3 mg/dL >/= 21 Years: 1.6 - 2.6 mg/dL | ||||
396 | |||||||
397 |
| Screan: Negative % Parasitemia: 0 % | |||||
398 | |||||||
399 |
| Not Detected | |||||
400 | |||||||
401 |
| Negative | |||||
402 | |||||||
403 |
| Interpretive Data: Methotrexate serum levels depend on indication for use, dosage, mode of administration, treatment regimen, individual pharmacokinetics, metabolism and other clinical factors. 24 hr: 5-10 umol/L 48 hr: 0.5-1.0 umol/L 72 hr: <0.2 umol/L | Interpretive Data: Methotrexate serum levels depend on indication for use, dosage, mode of administration, treatment regimen, individual pharmacokinetics, metabolism and other clinical factors. 24 hr: 5 - 10 umol/L 48 hr: 0.5 - 1.0 umol/L 72 hr: < 0.2 umol/L | ||||
404 | |||||||
405 |
| RANDOM: < 30 mg/L TIMED: Output: Reference: < 30 mg/24hr Interpretive Data: Normal: < 30 mg/24hr Microalbuminuria: 30 - 299 mg/24hr Macro clinical albuminuria: >/= 300 mg/24hr Concentration: Reference: < 20 ug/min Interpretive Data: Normal: < 20 ug/min Microalbuminuria: 20 - 199 ug/min Macro clinical albuminuria: >/= 200 ug/min | RANDOM: < 30 mg/L TIMED: Output: Reference: < 30 mg/24hr Interpretive Data: Normal: < 30 mg/24hr Microalbuminuria: 30 - 299 mg/24hr Macro clinical albuminuria: >/= 300 mg/24hr Concentration: Reference: < 20 ug/min Interpretive Data: Normal: < 20 ug/min Microalbuminuria: 20 - 199 ug/min Macro clinical albuminuria: >/= 200 ug/min | ||||
406 | |||||||
407 |
| < 30 mg/g Interpretive Data: Normal to Mildly Increased: < 30 mg/g Moderately Increased: 30 - 299 mg/g Severely Increased: >/= 300 mg/g Two of three specimens of microalbumin/creatinine ratio should be abnormal before considering a patient to have high or very high albuminuria. | < 30 mg/g Interpretive Data: Normal to Mildly Increased: < 30 mg/g Moderately Increased: 30 - 299 mg/g Severely Increased: >/= 300 mg/g Two of three specimens of microalbumin/creatinine ratio should be abnormal before considering a patient to have high or very high albuminuria. | ||||
408 | |||||||
409 |
| Negative | |||||
410 | |||||||
411 | 06/01/22 |
| < 3.5 U/mL Interpretive Data: < 3.5 Normal 3.5-5.0 Equivocal > 5.0 Positive The specificity of anti-MPO for systemic vasculitis and/or idiopathic crescentic glomerulonephritis is as high as 95% when groups of patients with renal disorders and diseases related to vasculitis are studied. However, MPO antibodies occur incidentally in other diseases such as drug induced lupus erythematosus, rheumatoid arthritis and inflammatory bowel disease. | ||||
412 | |||||||
413 |
| Not Detected | |||||
414 | |||||||
415 |
| Not Detected | |||||
416 | |||||||
417 | 09/06/22 |
| Male: < 93 ng/mL Female: < 81 ng/mL | ||||
418 | 09/06/22 | ||||||
419 |
| Negative | |||||
420 | |||||||
421 |
| Negative | |||||
422 | |||||||
423 |
| SERUM: 270 - 295 mOsm/kgH2O URINE: 50 - 1200 mOsm/kgH2O Interpretive Data: Varies significantly with hydration Average fluid intake 300 - 900 After 12 Hr fluid restriction > 850 | |||||
424 | |||||||
425 |
| ABBOTT: 9 - 77 pg/mL ROCHE: 15 - 65 pg/mL | 15 - 72 pg/mL | ||||
426 | |||||||
427 |
| ABBOTT: 9 - 77 pg/mL ROCHE: 15 - 65 pg/mL | 15 - 72 pg/mL | ||||
428 | |||||||
429 |
| <50% of baseline value | Interpretive Data: < 50 % of baseline value This assay has not been clinically validated for intraoperative use, however intraoperative measurements were included in assay validations performed by Abbott. | ||||
430 | |||||||
431 |
| 15 - 40 ug/mL | 15 - 40 ug/mL | ||||
432 | |||||||
433 |
| 0 - 14 Days: 5.6 - 10.5 mg/dL 15 Days - 11 Months: 4.8 - 8.4 mg/dL 1 - 4 Years: 4.3 - 6.8 mg/dL 5 - 12 Years: 4.1 - 5.9 mg/dL 13 - 15 Years: Male: 3.5 - 6.2 mg/dL Female: 3.2 - 5.5 mg/dL 16 - 18 Years: 2.9 - 5.0 mg/dL >/=19 Years: 2.3 - 4.7 mg/dL | 0 - 14 Days: 5.3 - 9.8 mg/dL 15 Days - 11 Months: 4.6 - 7.9 mg/dL 1 - 4 Years: 4.1 - 6.4 mg/dL 5 - 12 Years: 4.0 - 5.6 mg/dL 13 - 15 Years: Male: 3.5 - 5.8 mg/dL Female: 3.1 - 5.3 mg/dL 16 - 18 Years: 2.9 - 4.8 mg/dL >/=19 Years: 2.5 - 4.5 mg/dL | ||||
434 | |||||||
435 |
| Not Present | |||||
436 | |||||||
437 |
| ASPIRIN: 350 - 549 sec P2Y12: 50 - 208 sec SCREEN: Col/Epi: 78 - 177 sec Col/ADP: 50 – 102 sec | |||||
438 | |||||||
439 |
| Post Vas Total Sperm: Absent Post Vas Semen Volume: 0.5 - 5.0 mL Post Vas Nonmotile Sperm: < 1% Post Vas Motile Sperm: < 1% | |||||
440 | |||||||
441 |
| SERUM/PLASMA: 0 - 27 Days: 3.7 - 5.9 mmol/L 28 Days - 1 Year: 4.1 - 5.3 mmol/L 2 - 17 Years: 3.4 - 4.7 mmol/L >/= 18 Years: 3.5 - 5.1 mmol/L URINE: Random: Interpretive Data: No Reference Ranges Established Timed: 25.0 - 125.0 mmol/24 hr Interpretive Data: Varies significantly with hydration and diet. | SERUM/PLASMA: 0 - 27 Days: 3.7 - 5.9 mmol/L 28 Days - 1 Year: 4.1 - 5.3 mmol/L 2 - 17 Years: 3.4 - 4.7 mmol/L >/= 18 Years: 3.5 - 5.1 mmol/L URINE: Random: Interpretive Data: No Reference Ranges Established Timed: 25.0 - 125.0 mmol/24 hr Interpretive Data: Varies significantly with hydration and diet. | ||||
442 | |||||||
443 |
| 0 - 11 Months: 7.0 - 25.0 mg/dL 1 - 11 Years: 11 - 34.0 mg/dL >/= 12 Years: 14.0 - 45.0 mg/dL | 0 - 14 Days: </= 1.0 mg/dL 15 Days - 11 Months: 4.0 - 24.0 mg/dL 1 - 4 Years: 11.0 - 23.0 mg/dL 5 - 12 Years: 13.0 - 26.0 mg/dL 13 - 15 Years: 17.0 - 31.0 mg/dL 16 - 17 Years: Female: 16.0 - 33.0 mg/dL Male: 20.0 - 35.0 mg/dL >/= 18 Years: 20.0 - 40.0 mg/dL | ||||
444 | |||||||
445 |
| < 0.10 ng/mL Interpretive Data: < 0.5: On the first day of ICU admission is associated with a low risk for progression to severe sepsis and/or septic shock > 2.0: On the first day of ICU admission is associated with a high risk for progression to severe sepsis and/or septic shock Procalcitonin values are physiologically increased in neonates during the first two Days of life. The reference range applies from three Days after birth. | < 0.10 ng/mL Interpretive Data: < 0.5: On the first day of ICU admission is associated with a low risk for progression to severe sepsis and/or septic shock > 2.0: On the first day of ICU admission is associated with a high risk for progression to severe sepsis and/or septic shock Procalcitonin values are physiologically increased in neonates during the first two Days of life. The reference range applies from three Days after birth. | ||||
446 | |||||||
447 |
| Male: < 0.3 ng/mL Normal Menstruating Females: Follicular Phase: < 0.4 ng/mL Luteal Phase: 1.2 - 15.9 ng/mL Postmenopausal Females: <0.3 ng/mL Pregnant Females: First Trimester: 2.8 - 147.3 ng/mL Second Trimester: 22.5 - 95.3 ng/mL Third Trimester: 27.9 - 242.5 ng/mL | Male: < 0.2 ng/mL Female: Cycle Phase: Follicular: < 0.2 ng/mL Ovulation: 0.2 - 4.1 ng/mL Luteal: 4.1 - 14.5 ng/mL Menopausal: < 0.2 ng/mL Healthy Pregnant Females: 1st Trimester: 11.0 - 44.3 ng/mL 2nd Trimester: 25.4 - 83.4 ng/mL 3rd Trimester: 58.7 - 214.0 ng/mL | ||||
448 | |||||||
449 |
| 4 - 29 Days: 12.6 - 213.0 ng/mL 30 Days - 11 Months: 6.3 - 114.0 ng/mL 1 - 18 Years: 4.2 - 23.0 ng/mL >/= 19 Years: Male: 3.5 - 19.4 ng/mL Female: 5.2 - 26.5 ng/mL | 0 - 30 Days: 1.1 - 470.0 ng/mL 1 - 11 Months: 5.2 - 60.0 ng/mL 1 - 18 Years: 3.0 - 25.0 ng/mL >/= 19 Years: Male: 4.0 - 15.2 ng/mL Female (Non-Pregnant): 4.79 - 23.3 ng/mL | ||||
450 | |||||||
451 | 09/07/22 |
| 70 - 161 % | ||||
452 | 09/07/22 | ||||||
453 | 09/07/22 |
| 70 - 140 % | ||||
454 | 09/07/22 | ||||||
455 |
| SERUM: 0 - 14 Days: 5.3 - 8.3 g/dL 15 Days - 11 Months: 4.4 - 7.1 g/dL 1 - 5 Years: 6.1 - 7.5 g/dL 6 - 8 Years: 6.4 - 7.7 g/dL 9 - 18 Years: 6.5 - 8.1 g/dL >/= 19 Years: 6.2 - 8.3 g/dL URINE: Random: 10 - 140 mg/L Timed: < 300 mg/24 hr At Rest 50 - 80 mg/24 hr BODY FLUID: Interpretive Data: Pleural and Pericardial: Transudate effusions have a low concentration of Total Protein. Exudate effusions have a high concentration of Total Protein. Serous fluid Total Protein values >/=3.0 g/dL separate exudates from transudates. A ratio of serous fluid total protein to a simultaneously collected serum protein of >/=0.5 is predictive of an exudate. CSF: 0 - 30 Days: 20.0 - 80.0 mg/dL >/= 1 Month: 15.0 - 45.0 mg/dL | SERUM: 0 -14 Days: 5.1 - 8.0 g/dL 15 Days - 11 Months: 4.3 - 6.9 g/dL 1 - 5 Years: 5.9 - 7.3 g/dL 6 - 8 Years: 6.2 - 7.5 g/dL 9 - 18 Years: 6.3 - 7.8 g/dL >/=19 Years: 6.4 - 8.3 g/dL URINE: Concentration: No Established Reference Range Timed: < 300 mg/24 hr At Rest 50 - 80 mg/24 hr BODY FLUID: Interpretive Data: Pleural and Pericardial: Transudate effusions have a low concentration of Total Protein. Exudate effusions have a high concentration of Total Protein. Serous fluid Total Protein values >/=3.0 g/dL separate exudates from transudates. A ratio of serous fluid total protein to a simultaneously collected serum protein of >/=0.5 is predictive of an exudate. CSF: 0 - 30 Days: 20.0 - 80.0 mg/dL >/= 1 Month: 15.0 - 45.0 mg/dL | ||||
456 | |||||||
457 |
| < 0.2 mg/mg | < 0.2 mg/mg | ||||
458 | |||||||
459 |
| Albumin: 3.00 - 5.05 g/dL Alpha 1 Globulin: 0.13 - 0.36 g/dL Alpha 2 Globulin: 0.57 - 1.22 g/dL Beta: 0.69 - 1.33 g/dL Gamma Globulin: 0.63 - 2.00 g/dL Alb/Glob Ratio: 0.92 - 1.86 | |||||
460 | |||||||
461 |
| PT: 11.8 - 15.0 seconds INR: 0.8 - 1.2 | |||||
462 | |||||||
463 | 09/07/22 |
| No Inhibitor Detected | ||||
464 | 09/07/22 | ||||||
465 |
| 24 - 36 seconds | |||||
466 | |||||||
467 | 09/07/22 |
| No Inhibitor Detected | ||||
468 | 09/07/22 | ||||||
469 |
| TOTAL: < 4.1 ng/mL | |||||
470 | |||||||
471 | 06/27/22 |
| Negative | ||||
472 | |||||||
473 |
| . | |||||
474 |
| Not Detected | |||||
475 |
| Not Detected | |||||
476 |
| Not Detected | |||||
477 |
| Not Detected | |||||
478 |
| Not Detected | |||||
479 |
| Not Detected | |||||
480 |
| Not Detected | |||||
481 |
| Not Detected | |||||
482 |
| Not Detected | |||||
483 |
| Not Detected | |||||
484 |
| Not Detected | |||||
485 |
| Not Detected | |||||
486 |
| Not Detected | |||||
487 |
| Not Detected | |||||
488 |
| Not Detected | |||||
489 |
| Not Detected | |||||
490 |
| Not Detected | |||||
491 |
| Not Detected | |||||
492 |
| Not Detected | |||||
493 |
| Not Detected | |||||
494 |
| Not Detected | |||||
495 |
| Not Detected | |||||
496 | |||||||
497 |
| Negative | |||||
498 | |||||||
499 |
| RELATIVE 0 - 3 Days: 3.47 - 5.40 % 4 - 30 Days: 1.06 - 2.37 % 31 - 60 Days: 2.12 - 3.47 % 61 Days - 5 Months: 1.55 - 2.70 % 6 Months - 1 Year: 0.99 - 1.82 % 2 - 5 Years: 0.82 - 1.45 % 6 - 11 Years: 0.98 - 1.94 % 12 - 17 Years: 0.90 - 1.49 % >/= 18 Years: Male: 0.51 - 1.81 % Female: 0.50 - 1.70 % ABSOLUTE 0 - 3 Days: 0.15 - 0.22 Mil/uL 4 - 30 Days: 0.05 - 0.11 Mil/uL 31 - 60 Days: 0.05 - 0.08 Mil/uL 61 Days - 5 Months: 0.05 - 0.09 Mil/uL 6 Months - 1 Year: 0.04 - 0.11 Mil/uL 2 - 18 Years: 0.04 - 0.07 Mil/uL >/= 18 Years: Male: 0.03 - 0.01 Mil/uL Female: 0.02 - 0.08 Mil/uL IRF 1 - 3 Days: 30.50 - 35.10 % 4 - 30 Days: 14.50 - 24.60 % 31 - 60 Days: 19.10 - 28.90 % 2 - 5 Months: 13.40 - 23.30 % 6 - 23 Months: 11.40 - 25.80 % 2 - 5 Years: 8.40 - 21.70 % 6 - 11 Years: 8.90 - 24.10 % 12 - 17 Years: 9.00 - 18.70 % >/= 18 Years: Male: 9.30 - 17.40 % Female: 2.30 - 13.40 % HEMOGLOBIN EQUIVALENT Male: 0 - 5 Months: 27.6 - 38.7 pg 6 - 23 Months: 28.7 - 35.7 pg 2 - 5 Years: 27.7 - 37.8 pg 6 - 11 Years: 32.4 - 37.6 pg 12 - 17 Years: 30.3 - 40.4 pg >/= 18 Years: 36.0 - 38.6 pg Female: 0 - 5 Months: 29.2 - 37.5 pg 6 - 23 Months: 30.1 - 35.7 pg 2 - 5 Years: 29.3 - 37.3 pg 6 - 11 Years: 30.4 - 39.7 pg 12 - 17 Years: 29.9 - 38.4 pg >/= 18 Years: 30.6 - 40.7 pg | |||||
500 | |||||||
501 |
| < 30 IU/mL | < 14 IU/mL | ||||
502 | |||||||
503 |
| Negative | |||||
504 | |||||||
505 |
| Negative | |||||
506 | |||||||
507 |
| < 30 mg/dL | < 30 mg/dL | ||||
508 | |||||||
509 | 06/01/22 |
| < 2.0 U/mL Interpretive Data: < 2.0 Normal 2.0-3.0 Equivocal > 3.0 Positive Anti-PR3 antibodies are highly specific for GPA. However, PR3 antibodies are reported in infective disorders in monoclonal gammopathy and in a few cases of malignancy without signs of secondary vasculitis. | ||||
510 | |||||||
511 | 07/07/22 |
| Male: 11.2 - 78.1 nmol/L Female: 11.7 - 137.2 nmol/L | ||||
512 | 07/07/22 | ||||||
513 |
| Negative | |||||
514 | |||||||
515 |
| 5.0 - 15.0 ng/mL | This assay is not performed on Roche analyzers. | ||||
516 | |||||||
517 |
| SERUM: 0 - 26 Days: 133 - 146 mmol/L 27 - 1 Year: 139 - 146 mmol/L 2 - 17 Years: 138 - 145 mmol/L >/= 18 Years 136 - 145 mmol/L URINE: Random: No reference ranges established. Timed: Male: 6 - 10 Years: 41 - 115 mmol/24hr 10 - 14 Years 63 - 177 mmol/24hr >/= 14 Years: 40 - 220 mmol/24hr Female: 6 - 10 Years: 20 - 69 mmol/24hr 10 - 14 Years 48 - 168 mmol/24hr >/= 14 Years: 40 - 220 mmol/24hr Interpretive Data: Varies significantly with hydration and diet. | SERUM: 0 - 26 Days: 133 - 146 mmol/L 27 - 1 Year: 139 - 146 mmol/L 2 - 17 Years: 138 - 145 mmol/L >/= 18 Years 136 - 145 mmol/L URINE: Random: No reference ranges established. Timed: Male: 6 - 10 Years: 41 - 115 mmol/24hr 10 - 14 Years 63 - 177 mmol/24hr >/= 14 Years: 40 - 220 mmol/24hr Female: 6 - 10 Years: 20 - 69 mmol/24hr 10 - 14 Years 48 - 168 mmol/24hr >/= 14 Years: 40 - 220 mmol/24hr Interpretive Data: Varies significantly with hydration and diet. | ||||
518 | |||||||
519 |
| Negative | |||||
520 | |||||||
521 |
| Negative | |||||
522 | |||||||
523 |
| . | |||||
524 |
| Non-Reactive | Non-Reactive | ||||
525 |
| Non-Reactive | |||||
526 |
| Non-Reactive | |||||
527 | 07/18/22 |
| Non-Reactive | ||||
528 | |||||||
529 | 09/06/22 |
| Male and Female: 4 Days - 11 Months: 2.32 - 4.87 pg/mL 1 - 11 Years: 2.79 - 4.42 pg/mL 12 - 14 Years: Male: 2.89 - 4.33 pg/mL Female: 2.50 - 3.95 pg/mL 15 - 18 Years: Male: 2.25 - 3.85 pg/mL Female: 2.31 - 3.71 pg/mL >/= 19 Years: 1.71 - 3.71 pg/mL | ||||
530 | 09/06/22 | ||||||
531 | 09/06/22 |
| 4 Days - 11 Months: 85 - 234 ng/dL 1 - 11 Years: 113 - 189 ng/dL 12 - 14 Years: 98 - 176 ng/dL 15 - 16 Years: 93 - 156 ng/dL 17 - 18 Years: 90 -168 ng/dL >/= 19 Years: 58 - 159 ng/dL | ||||
532 | 09/06/22 | ||||||
533 |
| 0 - 11 Months: Male: 0.90-1.80 ng/dL Female: 0.90-1.60 ng/dL 1 - 10 Years: 0.80-1.60 ng/dL 11 - 20 Years: 0.80-1.40 ng/dL >/= 21 Years: 0.70-1.50 ng/dL | 0 - 30 Days: 1.24 - 3.89 ng/dL 1 - 11 Months: 1.09 - 1.71 ng/dL 1 - 18 Years: 1.01 - 1.63 ng/dL >/= 19 Years: 0.93 - 1.70 ng/dL | ||||
534 | |||||||
535 | 07/07/22 |
| 4.87 - 11.72 ug/dL | ||||
536 | 07/07/22 | ||||||
537 |
| 5.0 - 20.0 ng/mL | 5.0 - 20.0 ng/mL | ||||
538 | |||||||
539 |
| . | |||||
540 |
| R Plain 5.0 - 10.0 min K Plain 1.0 - 3.0 min Angle Plain 53.0 - 72.0 deg MA Plain 50.0 - 70.0 mm LY30 Plain 0.0 - 8.0 % R Heparin Treated 5.0 - 10.0 min K Heparin Treated 1.0 - 3.0 min Angle Heparin Treated 53.0 - 72.0 deg MA Heparin Treated 50.0 - 70.0 mm LY30 Heparin Treated 0.0 - 8.0 % | |||||
541 |
| R Rapid Plain 0.4 - 0.7 min K Rapid Plain 0.6 - 2.3 min Angle Rapid Plain 64.0 - 80.0 deg MA Rapid Plain 52.0 - 71.0 mm LY30 Rapid Plain 0.0 - 8.0 % TEG ACT Plain 86.0 - 118.0 sec R Rapid Heparin Treated 0.4 - 0.7 min K Rapid Heparin Treated 0.6 - 2.3 min Angle Rapid Heparin Treated 64.0 - 80.0 deg MA Rapid Heparin Treated 52.0 - 71.0 mm LY30 Rapid Heparin Treated 0.0 - 8.0 % TEG ACT Heparin Treated 86.0 - 118.0 sec | |||||
542 |
| R Plain 5.0 - 10.0 min K Plain 1.0 - 3.0 min Angle Plain 53.0 - 72.0 deg MA Plain 50.0 - 70.0 mm LY30 Plain 0.0 - 8.0 % R Heparin Treated 5.0 - 10.0 min K Heparin Treated 1.0 - 3.0 min Angle Heparin Treated 53.0 - 72.0 deg MA Heparin Treated 50.0 - 70.0 mm LY30 Heparin Treated 0.0 - 8.0 % | |||||
543 |
| MA Functional Fibrinogen 11.5 - 31.6 mm TEG Functional Fibrinogen 210.6 - 576.4 mg/dL | |||||
544 |
| R-TEG 4.6 - 9.1 minutes K-TEG 0.8 - 2.1 minutes Angle-TEG 63.0 - 78.0 degrees MA-TEG 52.0 - 69.0 mm MA-TEG, Rapid 52.0 - 70.0 mm R-TEG, w/Hep 4.3 - 8.3 minutes MA Functional Fibrinogen 15.0 - 32.0 mm FLEV 278.0 - 581.0 mg/dL | |||||
545 |
| R-TEG 4.6 - 9.1 minutes MA-TEG, Rapid 52.0 - 70.0 mm MA Functional Fibrinogen 15.0 - 32.0 mm LY30-TEG <= 2.6 % | |||||
546 | |||||||
547 | 09/06/22 |
| Male: 21 - 49 Years: 240 - 871 ng/dL >/= 50 Years: 221 - 716 ng/dL Female: Premenopausal 21 - 49 Years: 14 - 53 ng/dL Postmenopausal >/= 50 Years: 12 - 36 ng/dL | ||||
548 | 09/06/22 | ||||||
549 | 07/07/22 |
| 5 - 20 ug/mL | ||||
550 | 07/07/22 | ||||||
551 | 09/07/22 |
| 13.0 - 21.0 seconds | ||||
552 | 09/07/22 | ||||||
553 | 07/07/22 |
| < 4.1 IU/mL | ||||
554 | 07/07/22 | ||||||
555 | 07/07/22 |
| < 5.6 IU/mL | ||||
556 | 07/07/22 | ||||||
557 | 06/01/22 |
| < 7.0 EliA u/mL Interpretive Data: 0.1-6.9: Negative 7.0-10.0: Equivocal >1 0.0: Positive | ||||
558 | |||||||
559 |
| TROUGH: 0 - 2 Months < 1.1 ug/mL >/= 3 Months < 2.0 ug/mL PEAK: 5.0 - 10.0 ug/mL RANDOM: 2.0 - 10.0 ug/mL | TROUGH: 0 - 2 Months < 1.1 ug/mL >/= 3 Months < 2.0 ug/mL PEAK: 5.0 - 10.0 ug/mL RANDOM: 2.0 - 10.0 ug/mL | ||||
560 | |||||||
561 | 07/11/22 |
| Negative | ||||
562 | 07/11/22 | ||||||
563 |
| 0 - 62 Days: 104 - 224 mg/dL 63 Days - 11 Months: 107 - 324 mg/dL 1 - 59 Years: Male: 174 - 364 mg/dL Female: 180 - 382 mg/dL >/= 60 Years: Male:163 - 344 mg/dL Female:173 - 360 mg/dL | 0 - 56 Days: 111 - 243 mg/dL 57 Days - 11 Months: 115 - 352 mg/dL 1 - 17 Years: 238 - 366 mg/dL >/= 18 Years 200 - 360 mg/dL | ||||
564 | |||||||
565 |
| Male: 20 - 50 % Female: 15 - 50 % | Male: 20 - 50 % Female: 15 - 50 % | ||||
566 | |||||||
567 |
| Negative | |||||
568 | |||||||
569 |
| < 0.03 ng/mL | |||||
570 | |||||||
571 |
| 4 Days - 5 Months: 0.730 - 4.770 uIU/mL 6 Months - 13 Years: 0.700 - 4.170 uIU/mL 14 - 18 Years: 0.470 - 3.410 uIU/mL >/= 19 Years: 0.350 - 4.940 uIU/mL | 0 - 30 Days: 1.230 - 27.200 uIU/ml 1 - 11 Months: 1.030 - 6.800 uIU/ml 1 - 14 Years: 1.120 - 5.010 uIU/ml 15 - 18 Years: 0.680 - 4.090 uIU/ml >/= 19 Years: 0.270 - 4.200 uIU/ml | ||||
572 | |||||||
573 |
| Varies significantly with hydration. 0 - 2 Days: 30-60 mL/24 hr 3 - 9 Days: 100-300 mL/24 hr 10 Days - 1 Month: 250-450 mL/24 hr 2 - 11 Months: 400-500 mL/24 hr 1 - 2 Years: 500-600 mL/24 hr 3 - 4 Years: 600-700 mL/24 hr 5 - 7 Years: 650-1000 mL/24 hr 8 - 14 Years: 800-1400 mL/24 hr 15 - 59 Years: Male: 800-1800 mL/24 hr Female: 600-1600 mL/24 hr >/= 60 Years: 250-2400 mL/24 hr | Varies significantly with hydration. 0 - 2 Days: 30-60 mL/24 hr 3 - 9 Days: 100-300 mL/24 hr 10 Days - 1 Month: 250-450 mL/24 hr 2 - 11 Months: 400-500 mL/24 hr 1 - 2 Years: 500-600 mL/24 hr 3 - 4 Years: 600-700 mL/24 hr 5 - 7 Years: 650-1000 mL/24 hr 8 - 14 Years: 800-1400 mL/24 hr 15 - 59 Years: Male: 800-1800 mL/24 hr Female: 600-1600 mL/24 hr >/= 60 Years: 250-2400 mL/24 hr | ||||
574 | |||||||
575 |
| 0.30 - 0.70 IU/mL | |||||
576 | |||||||
577 |
| BLOOD (BUN): Male: 0 - 14 Days: 3 - 22 mg/dL 15 Days - 11 Months: 4 - 17 mg/dL 1 - 9 Years: 9 - 22 mg/dL 10 - 18 Years: 7 - 20 mg/dL 19 - 49 Years: 9 - 21 mg/dL >/= 50 Years: 8 - 26 mg/dL Female: 0 - 14 Days: 3 - 22 mg/dL 15 Days - 11 Months: 4 - 17 mg/dL 1 - 9 Years: 9 - 22 mg/dL >/= 10 Years: 7 - 20 mg/dL URINE: Random: No Reference Ranges Established Timed: 3,000-5,000 mg/6 Hrs 12,000 - 20,000 mg/24 Hrs | BLOOD (BUN) 0 - 7 Days: 3 - 25 mg/dL 8 Days - 11 Months: 4 - 19 mg/dL 1 - 18 Years: 5 - 18mg/dL 19 - 59 Years: 6 - 20 mg/dL 60 - 90 Years: 8 - 23 mg/dL >/= 91 Years: 10 - 31 mg/dL URINE: Random: No Reference Ranges Established Timed: 3,000-5,000 mg/6 Hrs 12,000 - 20,000 mg/24 Hrs | ||||
578 | |||||||
579 |
| 0 - 14 Days: 2.8 - 12.0 mg/dL 15 Days - 11 Months: 1.6 - 6.3 mg/dL 1 - 11 Years: 1.8 - 4.9 mg/dL 12 - 18 Years: Male: 2.6 - 7.6 mg/dL Female: 2.6 - 5.9 mg/dL >/= 19 Years: Male: 3.5 - 7.2 mg/dL Female: 2.6 - 6.0 mg/dL | 0 - 14 Days: 2.7 - 12.0 mg/dL 15 Days - 11 Months: 1.5 - 6.2 mg/dL 1 - 11 Years: 1.7 - 4.7 mg/dL 12 - 18 Years: Female: 2.5 - 5.7 mg/dL Male: 2.5 - 7.5 mg/dL >/= 19 Years: Male: 3.4 - 7.0 mg/dL Female: 2.4 - 5.7 mg/dL | ||||
580 | |||||||
581 |
| . | |||||
582 |
| . | |||||
583 |
| Clear, Slightly Hazy, Hazy | |||||
584 |
| 1.003 - 1.035 | |||||
585 |
| 4.6 - 8.0 | |||||
586 |
| Negative | |||||
587 |
| Negative | |||||
588 |
| Negative | |||||
589 |
| Negative | |||||
590 |
| Negative | |||||
591 |
| Negative | |||||
592 |
| < 2.0 mg/dL | |||||
593 |
| Negative | |||||
594 |
| . | |||||
595 |
| 0 - 5 /HPF | |||||
596 |
| 0 - 2 /HPF | |||||
597 |
| </= 8 /LPF | |||||
598 |
| 0 /LPF | |||||
599 |
| < Moderate | |||||
600 |
| 0 - 3 /LPF | |||||
601 |
| 0 /LPF | |||||
602 | |||||||
603 |
| . | |||||
604 |
| Negative | |||||
605 |
| Negative | |||||
606 |
| Negative | |||||
607 | |||||||
608 |
| TOTAL: 50 - 125 ug/mL FREE: 6 - 22 ug/mL FREE %: 5 - 18 % | TOTAL: 50 - 125 ug/mL FREE: 6 - 22 ug/mL FREE %: 5 - 18 % | ||||
609 | |||||||
610 |
| TROUGH: 10.0 - 20.0 ug/mL PEAK: 30.0 - 50.0 ug/mL RANDOM: 5.0 - 40.0 ug/mL | TROUGH: 10.0 - 20.0 ug/mL PEAK: 30.0 - 50.0 ug/mL RANDOM: 5.0 - 40.0 ug/mL | ||||
611 | |||||||
612 | 07/05/22 |
| Negative | ||||
613 | |||||||
614 |
| 213 - 816 pg/mL | 232 - 1245 pg/mL | ||||
615 | |||||||
616 | 09/06/22 |
| 30 - 100 ng/mL Interpretive Data: < 20: Deficiency 20-29: Insufficiency 30-100: Sufficiency > 150: Possible Toxicity | ||||
617 | 09/06/22 | ||||||
618 |
| None Seen/Not Present | |||||
619 | |||||||
620 |
| ||||||
621 |
| 74 - 152 seconds | |||||
622 | |||||||
623 |
| 74 - 152 seconds | |||||
624 | |||||||
625 |
| Male: 0 - 14 Days: 3 - 22 mg/dL 15 Days - 11 Months: 4 - 17 mg/dL 1 - 9 Years: 9 - 22 mg/dL 10 - 18 Years: 7 - 20 mg/dL 19 - 49 Years: 9 - 21 mg/dL >/= 50 Years 8 - 26 mg/dL Female: 0 - 14 Days: 3 - 22 mg/dL 15 Days - 11 Months: 4 - 17 mg/dL 1 - 9 Years: 9 - 22 mg/dL >/= 10 Years: 7 - 20 mg/dL | |||||
626 | |||||||
627 |
| 0 - 29 Days: 98 - 113 mmol/L >/= 30 Days: 98 - 107 mmol/L | |||||
628 | |||||||
629 |
| 0 - 27 Days: 15 - 22 mmol/L 28 Days - 11 Months: 20 - 28 mmol/L >/= 1 Year: 20 - 30 mmol/L | |||||
630 | |||||||
631 |
| 10 - 20 | |||||
632 | |||||||
633 |
| 0 - 14 Days: 0.4 - 1.1 mg/dL 15 Days - 11 Months: 0.3 - 0.5 mg/dL 1 - 11 Years: 0.4 - 0.7 mg/dL 12 - 14 Years: 0.6 - 0.8 mg/dL 15 - 17 Years: Male: 0.7 - 1.1 mg/dL Female: 0.6 - 0.9 mg/dL >/= 18 Years: Male: 0.7 - 1.3 mg/dL Female: 0.6 - 1.1 mg/dL | |||||
634 | |||||||
635 |
| < 60 mL/min/1.73 sq meter | |||||
636 | |||||||
637 |
| NICU Inpatient Locations: 51 - 60 mg/dL 0 - 23 Hours: 40 - 60 mg/dL 1 - 11 Months: 54 - 80 mg/dL >/= 1 Year: 70 - 99 mg/dL | |||||
638 | |||||||
639 |
| Male: 0 - 14 Days: 39.8 - 53.6 % 15 - 30 Days: 30.5 - 45.0 % 31 - 60 Days: 26.8 - 37.5 % 2 - 5 Months: 28.6 - 37.2 % 6 - 23 Months: 30.8 - 37.8 % 2 - 5 Years: 31.0 - 37.7 % 6 - 11 Years: 32.2 - 39.8 % 12 - 17 Years: 33.9 - 43.5 % >/= 18 Years: 39.4 - 51.6 % Female: 0 - 14 Days: 39.6 - 57.2 % 15 - 30 Days: 32.0 - 44.5 % 31 - 60 Days: 27.7 - 35.1 % 2 - 5 Months: 29.5 - 37.1 % 6 - 23 Months: 30.9 - 37.9 % 2 - 5 Years: 31.2 - 37.8 % 6 - 11 Years: 32.4 - 39.5 % 12 - 17 Years: 33.4 - 40.4 % >/= 18 Years: 35.6 - 47.3 % | |||||
640 | |||||||
641 |
| Male: 0 - 14 Days: 13.9 - 19.1 g/dL 15 - 30 Days: 10.0 - 15.3 g/dL 31 - 60 Days: 8.9 - 12.7 g/dL 2 - 5 Months: 9.6 - 12.4 g/dL 6 - 23 Months: 10.1 - 12.5 g/dL 2 - 5 Years: 10.2 - 12.7 g/dL 6 - 11 Years: 10.7 - 13.4 g/dL 12 - 17 Years: 11.0 - 14.5 g/dL >/= 18 Years: 12.7 - 17.2 g/dL Female: 0 - 14 Days: 13.4 - 20.0 g/dL 15 - 30 Days: 10.8 - 14.6 g/dL 31 - 60 Days: 9.2 - 11.4 g/dL 2 - 5 Months: 9.9 - 12.4 g/dL 6 Months - 5 Years: 10.2 - 12.7 g/dL 6 - 11 Years: 10.6 - 13.2 g/dL 12 - 17 Years: 10.8 - 13.3 g/dL >/= 18 Years: 11.0 - 15.4 g/dL | |||||
642 | |||||||
643 |
| 1.13 - 1.33 mmol/L | |||||
644 | |||||||
645 |
| 0 - 27 Days: 3.7 - 5.9 mmol/L 28 Days - 1 Year: 4.1 - 5.3 mmol/L 2 - 17 Years: 3.4 - 4.7 mmol/L >/= 18 Years: 3.5 - 5.1 mmol/L | |||||
646 | |||||||
647 |
| 0 - 26 Days: 133 - 146 mmol/L 27 Days - 1 Year: 139 - 146 mmol/L 2 - 17 Years: 138 - 146 mmol/L >/= 18 Years: 136 - 145 mmol/L | |||||
648 | |||||||
649 |
| 0 - 27 Days: 15 - 22 mmol/L 28 Days - 1 Year: 20 - 28 mmol/L >/= 1 Year: 20 - 30 mmol/L | |||||
650 | |||||||
651 |
| i-STAT: </= 0.08 ng/mL | |||||
652 | |||||||
653 |
| . | |||||
654 |
| Prisma Health Baptist Parkridge Respiratory Therapy 400 Palmetto Health Parkway Columbia, SC 29212 | |||||
655 |
| Prisma Health Tuomey Hospital Laboratory 129 North Washington Street Sumter, SC 29150 | |||||
656 | |||||||
657 |
| REFERENCE: | |||||
658 |
| . | |||||
659 |
| . | |||||
660 |
| 7.35 – 7.45 | |||||
661 |
| 35 – 45 mmHg | |||||
662 |
| . | |||||
663 |
| 45 - 100 mmHg | |||||
664 |
| 80 - 100 mmHg | |||||
665 |
| 96.0 – 100.0 % | |||||
666 |
| 22.0 – 26.0 mmol/L | |||||
667 |
| 95.0 – 98.0 % | |||||
668 |
| 0.0 – 4.9 % | |||||
669 |
| 0.0 – 3.00 % | |||||
670 |
| . | |||||
671 |
| . | |||||
672 |
| 7.32 – 7.42 | |||||
673 |
| 41 - 51 mmHg | |||||
674 |
| 30 - 50 mmHg | |||||
675 |
| 70.0 – 85.0 % | |||||
676 |
| ||||||
677 |
| 22.0 – 24.0 mmol/L | |||||
678 |
| 22.0 - 26.0 mmol/L | |||||
679 |
| 70.0 – 85.0 % | |||||
680 |
| 0.0 – 4.9 % | |||||
681 |
| 0.0 – 3.00 % | |||||
682 |
| . | |||||
683 |
| . | |||||
684 |
| 7.30 – 7.45 | |||||
685 |
| 35 - 50 mmHg | |||||
686 |
| 45 - 55 mmHg | |||||
687 |
| 92.0 – 100.0 % | |||||
688 |
| 22.0 – 26.0 mmol/L | |||||
689 |
| 92.0 – 100.0 % | |||||
690 |
| 0.0 – 4.9 % | |||||
691 |
| 0.0 – 3.00 % | |||||
692 |
| . | |||||
693 |
| . | |||||
694 |
| 7.32 – 7.45 | |||||
695 |
| 41 – 51 mmHg | |||||
696 |
| 35 - 54 mmHg | |||||
697 |
| 70.0 – 85.0 % | |||||
698 |
| ||||||
699 |
| 22.0 – 24.0 mmol/L | |||||
700 |
| 22.0 - 26.0 mmol/L | |||||
701 |
| 70.0 – 85.0 % | |||||
702 |
| 0.0 – 4.9 % | |||||
703 |
| 0.0 – 3.00 % | |||||
704 |
| . | |||||
705 |
| . | |||||
706 |
| 7.32 – 7.42 | |||||
707 |
| 41 - 51 mmHg | |||||
708 |
| 30 - 50 mmHg | |||||
709 |
| 10.0 – 100.0 % | |||||
710 |
| 22.0 – 24.0 mmol/L | |||||
711 |
| . | |||||
712 |
| . | |||||
713 |
| 7.32 – 7.42 | |||||
714 |
| 41 - 51 mmHg | |||||
715 |
| 30 - 50 mmHg | |||||
716 |
| 10.0 – 100.0 % | |||||
717 |
| 22.0 – 24.0 mmol/L | |||||
718 |
| . | |||||
719 |
| . | |||||
720 |
| 39.6 – 57.2 % | |||||
721 |
| . | |||||
722 |
| 34.1 – 44.9 % | |||||
723 |
| 40.1 – 51.1 % | |||||
724 |
| . | |||||
725 |
| 13.4 – 20.0 g/dL | |||||
726 |
| . | |||||
727 |
| 11.0 – 15.4 g/dL | |||||
728 |
| 12.7 – 17.2 g/dL | |||||
729 |
| . | |||||
730 |
| 133 - 146 mmol/L | |||||
731 |
| 136 - 145 mmol/L | |||||
732 |
| . | |||||
733 |
| 3.7 – 5.9 mmol/L | |||||
734 |
| 3.5 – 5.1 mmol/L | |||||
735 |
| . | |||||
736 |
| 98 - 113 mmol/L | |||||
737 |
| 98 - 107 mmol/L | |||||
738 |
| 1.13 – 1.33 mmol/L | |||||
739 |
| . | |||||
740 |
| 51 - 60 mg/dL | |||||
741 |
| 40 - 60 mg/dL | |||||
742 |
| 70 - 99 mg/dL | |||||
743 |
| 0.5 – 2.2 mmol/L |